Abbreviations :

• A : Adriamycin^© (doxorubicin) or araC or L-asparaginase
• B : bleomycin or BCNU
• C : cyclophosphamide or CCNU or cisplatin or carboplatin
• D : dacarbazine or dexamethasone
• E : etoposide
• F : 5-FU or fludarabine
• G : gemcitabine
• H : hydroxydaunomycin / doxorubicin
• I : ifosfamide or irinotecan or idarubicin
• L : leucovorin or L-asparaginase
• M : methotrexate or Matulane^© (procarbazine) or mitomycin C or mesna or mechlorethamine or mitoxantrone
• N : Novantrone^© (mitoxantrone)
• O : Oncovin^© (vincristine)
• P : prednisone or procarbazine or Platinol^© (cisplatin) or PS-341 / bortezomib
• Q : /
• R : rituximab
• S : Solu-Medrol (methylprednisolone)
• T : tamoxifen or thalidomide or thioguanine or thiotepa or topotecan
• U : /
• V : VM-26 / teniposide or vindesine or vinblastine or vinorelbine or Velcade^© (bortezomib)

• CHOP (hydroxydaunomycin / doxorubicin 50 mg/m² IV day 1 => Oncovin^© (vincristine) 1.4 mg/m² (maximum 2 mg) IV day 1 => cyclophosphamide 750 mg/m² IV day 1, prednisone 100 mg/day PO days 1-5, filgrastim 300 mg/day (< 75 kg) or 480 mg (>= 75 kg) subcutaneously days 4-1. Patients with initial bulky disease received 36 Gy radiotherapy to these areas irrespective of the results of chemotherapy. CNS prophylaxis was recommended for patients with lymphoblastic disease and consisted of methotrexate 15 mg intratechal on days 1, 4 of the first chemotherapy cycle and a whole brain radiotherapy with 25.2 Gy given after the end of chemotherapy. Leukopenia grade 3-4 (61-75 years : 72%; 15-60 years : 34%) or grade 4 (91%), grade 4 febrile neutropenia (47%), anemia (61-75 years : 13%; 15-60 years : 4%), grade 3-4 infection (61-75 years : 8%; 15-60 years : 4%), thrombocytopenia (61-75 years : 5%; 15-60 years : 2%), mucositis (2%; 15-60 years : 3%), alopecia (24%; 61-75 years : 63%; 15-60 years : 64%), nausea/vomiting (16%; 61-75 years : 8%; 15-60 years : 12%), diarrhea (2%), pulmonary toxicity (61-75 years : 4%), cardiotoxicity (2%; 61-75 years : 3%; 15-60 years < 1%), neurologic toxicity (7%; 61-75 years : 3%) => median relative dose intensity was 97% (61-75 years), median relative dose intensity was 98% (15-60 years), RBC transfusions necessary in 25% of patients (61-75 years), RBC transfusions necessary in 4% of patients (15-60 years), platelet transfusions necessary in 2% of patients aged 61-75 years and < 1% of patients aged 15-60 years, intravenous antibiotic therapy necessary in 38% of patients aged 61-75 years, and 25% of patients aged 15-60 years^ref. Among 418 patients treated in 3 consecutive national phase III studies, the rate of complete remission was 53% and the survival rate was 30% after 12 years of follow-up (Coltman CA, Dahlberg S, Jones SE, et al. Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. In: Kimura K, ed. Cancer chemotherapy: challenges for the future. Tokyo, Japan: Excerpta Medica, 1988:194-202; Bjorkholm et al. Blood 94 (1999) 599a). CNS prophylaxis was recommede for patients with lymphoblastic disease and consisted of methotrexate 15 mg intratechal on days 1, 4 of the first chemotherapy cycle and whole brain radiotherapy with 25.2 Gy given after the end of chemotherapy. A prephase treatment of vincristine 1 mg and prednisone 100 mg PO for 5-7 days was recommended to improve the performance status of the patients and to ameliorate the side effects of the first cycle of chemotherapy. Grade 3-4 leukopenia 70%, grade 3-4 anemia (20%), infection (11%), thrombocytopenia (15%), mucositis (7%), alopecia (58%), nausea/vomiting (14%), cardiotoxicity (5%), pulmomary toxicity (5%), neurologic toxicity (4%) => median relative dose intensity was 93%, RBC transfusions necessary in 40% of patients, platelet transfusions in 4%, intravenous antibiotic in 48%. Emetogenic potential day 1 level 4^ref
• CHOP-14 : repeat cycle every 14 days for 6 cycles.
• CHOP-21 : repeat cycle every 14 days for 8 cycles
• CHOP-R (CHOP + rituximab 375 mg/m² IV day 1 (day 8 at cycle 1). Repeat cycle every 14 days (21 days. Appropriate premedications. Grade 4 neutropenia (91%), grade 3-4 anemia (14%), fever (2%), infection (12%), mucositis (3%), alopecia (39%), infusion-related (9%), cardiac toxicity (8%), lung toxicity (8%), neurologic toxicity (5%), herpes zoster (4%), nausea/vomiting (4%), liver toxicity (3%), constipation (2%), renal toxicity (1%) => 43% required filgrastim. Emetogenic potential day 1 level 4^ref.
• CHOP-R-14
• CHOP-R-21
• CHOP-RA : CHOP-R + Avastin^© (bevacizumab)
• CHOPE (cyclophosphamide, Halotestin^© (fluoxymesterone), Oncovin^© (vincristine), prednisone, etoposide)
• CHOEP : see CHOPE
• MegaCHOEP : 4 courses of dose-escalated CHOEP. With course 1, cyclophosphamide (C) was given at a dose of 750 mg/m² on days 1 and 2, doxorubicin (H) at 35 mg/m² on days 1 and 2, Oncovin^© (vincristine) (O) at 2 mg on day 1, etoposide (E) at 150 mg/m² in DL1 and 200 mg/m² in DL2 on days 1 through 3, and prednisone (P) at 100 mg on days 1 through 5. With courses 2 and 3 the doses of C and E were increased: C 2250 mg/m² days 1 and 2, E 100 mg/m² twice daily on days 1 through 3. With course 4, C was further escalated to 3000 mg/m² on days 1 and 2, E (125 mg/m²) was given twice daily on days 1 through 4. At DL2 the dose of etoposide was further increased; during courses 2 and 3 E was given at 160 mg/m2 twice daily (days 1-3), and in course 4, E was set at 185 mg/m² twice daily (days 1-4). To allow for the shortest possible time between chemotherapy courses, time intervals between courses were not fixed. The next course of chemotherapy was to begin as soon as recovery of hematopoiesis was accomplished and nonhematologic toxicities of the preceding therapy had resolved. A platelet count higher than 80 x 10⁹/L (80/nL) was defined as trigger value for hematopoietic recovery^ref.
• CHOEP-14
• CHOEP-21 (CHOP + etoposide 100 mg/m² days 1-3. Repeat cycle every 21 days. Patients with initial bulky disease received 36 Gy radiotherapy to these areas irrespective of the results of chemotherapy. Grade 3-4 leukopenia (74%), anemia (9%), infection (4%), thrombocytopenia (7%), mucositis (2%), alopecia (71%), nausea/vomiting (9%), cardiotoxicity (3%), neurologic toxicity (2%), pulmonary toxicity (2%) => median relative dose intensity was 97%, RBC transfusions necessary in 11% of patients, platelet transfusions necessary in 2% of patients, intravenous antibiotic therapy necessary in 41% of patients, filgrastim administration was at the treating physician's discretion, and after the fifth cycle, 17% of patients received filgrastim)^ref
• first-generation regimens (FGR), which generally included 4 chemotherapeutic agents, produced complete remission in 45 to 55 percent of patients and cure in approximately 30-35%^{ref1, ref2, ref3} (Coltman CA, Dahlberg S, Jones SE, et al. Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. In: Kimura K, ed. Cancer chemotherapy: challenges for the future. Tokyo, Japan: Excerpta Medica, 1988:194-202)
• BACOP (bleomycin, Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), prednisone)
• CHVmP / CHVP (cyclophosphamide 600 mg/m² IV d1, hydroxydaunomycin / doxorubicin 50 mg/m² IV d1, VM-26 / teniposide 60 mg/m² IV d1 and prednisone PO d1-5 ) repeated every 3 weeks
• CHVP : cyclophosphamide 750 mg/m² i.v. infusion, hydroxydaunomycin / doxorubicin 25 mg/m² i.v., and vindesine 3 mg/m² i.v. on day 1, prednisone 50 mg/m² on days 1–5^ref
• CHVmP/BV (CHVmP with bleomycin 6 mg/m² IM/IV and vincristine 1.4 mg/m² IV added at mid-cycle (d15))
• COMLA (cyclophosphamide 1.5 g/m² day 1; Oncovin^© (vincristine)1.4 mg/m² days 1, 8, and 15; methotrexate 120 mg/m² days 22, 29, 36, 43, 50, 57, 64, and 71; and leucovorin 25 mg/m² every 6 hours X 4, beginning 24 hours after methotrexate; and cytosine arabinoside 300 mg/m²)^ref
• COPP (CCNU, Oncovin^© (vincristine), procarbazine, prednisone OR cyclophosphamide, Oncovin^© (vincristine), procarbazine, prednisone)
• COPP-ABVD (bleomycin 10 mg/m² on days 29, 43, Adriamycin^© (doxorubicin) 25 mg/m² on days 29, 43, cyclophosphamide 650 mg/m² on days 1, 8, Oncovin^© (vincristine) 1.4 mg/m² days 1, 8, procarbazine 100 mg/m² on days 1-14, prednisone 40 mg/m² on days 1-14, vinblastine 6 mg/m² on days 29, 43, dacarbazine 375 mg/m² on days 29, 43). Leukopenia grade 3 (52%) and 4 (19%), thrombocytopenia grade 3 (4%) or 4 (2%), anemia grade 3 (4%) or 4 (1%), infection grade 3 (2%) or 4 (1%), grade 3-4 mucositis (1%), respiratory tract effects (2%), nausea (20%), digestive tract effects (3%), neurologic effects (4%), skin effects (1%), pain (2%), hair loss (36%)^ref
• second-generation CHOP-like regimens (SGR) used 6-8 chemotherapeutic drugs^ref
• CAVPE (cyclophosphamide, Adriamycin^© (doxorubicin), vincristine, prednisone and etoposide)
• COP-BLAM (cyclophosphamide, Oncovin^©(vincristine), prednisone, bleomycin, Adriamycin^© (doxorubicin), Matulane^© (procarbazine))
• COP-BLAM I : cyclophosphamide 700 mg/m² IV day 1, Oncovin^© (vincristine)  1 mg/m₂ IV  days 1 and 15 in cycles 1 through 3, day 1 only in cycles 4 through 6, prednisone 50 mg/m2 PO days 1 through 7, bleomycin 15 mg IV day 15, Adriamycin^© (doxorubicin) 60 mg/m₂ IV  day 1, Matulane^© (procarbazine) 100 mg/m² PO days 1 through 7). Mesna (400 mg IV) was administered as a uroprotective

agent 0, 4, and 8 hours after CY. Courses were repeated every 3 weeks unless delayed by hematologic toxicity or infection. Cycles were delayed for 3 to 7 days if white blood cell counts (WBC) were < 2.5 X 10⁹/L or platelets < 75 X 10⁹/L on day 22. If these limits were not reached by day 28 of a cycle, but WBCs were higher than 2 X 10⁹/L and platelets higher than 50 X 10⁹/L, treatment was continued with a reduced dose (75% of scheduled dose for CY, DOX, VR, PROC). If these lower limits were not achieved, treatment was delayed for a further week and a BM cytology control performed^{ref1, ref2}
• COP-BLAM II :
• COP-BLAM III^ref :
• COP-BLAM V
• THP-COPBLM
• M-BACOD (high-dose methotrexate, bleomycin, Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), dexamethasone). the projected 5-year survival rate for both m-BACOD and M-BACOD is now 54%^ref, much lower than the initially projected rate of 64%^ref
• m-BACOD :
• standard dose : moderate-dose methotrexate IV 200 mg/m² day 15, bleomycin IV 4 U/m² day 1, Adriamycin^© IV 45 mg/m² day 1, cyclophosphamide IV 600 mg/m² day 1, Oncovin^© (vincristine) 1.4 mg/m² day 1, dexamethasone PO 6 mg/m² days 1-5, GM-CSF SC 5 mg/kg days 4-13
• low dose for HIV-associated NHL : methotrexate IV 200 mg/m² day 15, bleomycin IV 4 U/m² day 1, Adriamycin^© IV 25 mg/m² day 1, cyclophosphamide IV 300 mg/m² day 1, Oncovin^© (vincristine) 1.4 mg/m² day 1, dexamethasone PO 3 mg/m² days 1-5^ref
Meningeal lymphoma prophylaxis in cycle 1 only : cytarabine 50 mg, IT days 1, 8, 15 and 22
Pneumocystis prophylaxis : trimethoprim/sulfamethoxazole, dapsone or inhaled pentamidine
• third-generation CHOP-like regimens (SGR) : initially, each of these centers reported complete-remission rates of 70 to 85% and predicted long-term survival of 55 to 65%, but follow-up was limited and these new treatment programs were more difficult to administer, more toxic, and more costly. Because overall survival and survival without treatment failure in the CHOP group were not significantly different from survival in the three other groups, and because the rate of severe toxic reactions and the cost of the CHOP regimen are lower, CHOP remains the best available treatment for patients with advanced-stage, intermediate-grade or high-grade non-Hodgkin's lymphoma^ref.
• MACOP-B (methotrexate 100 mg/m² IV bolus or 300 mg/m² IV over 4 hours on days 8, 36, and 64, Adriamycin^© (doxorubicin) 50 mg/m² (round to nearest 1 mg) IV on days 1, 15, 29, 43, 57, and 71, cyclophosphamide 350 mg/m² (round to nearest 10 mg) IV on days 1, 15, 29, 43, 57, and 71, Oncovin^© (vincristine) (round to nearest 0.1 mg) 1.4 mg/m² IV on days 8, 22, 36, 50, 64, and 78, prednisone 75 mg PO daily for 10 weeks, then taper over next 15 days (outpatient prescription in multiples of 5 mg or 50 mg tablets), bleomycin 10 units/m² IV on days 22, 50, and 78 (round to nearest 1 units; leucovorin 15 mg PO q6h for 6 doses, starting 24 hours after methotrexate). weekly treatment for a total of 12 weeks. Grade 4 neutropenia (21%), grade 3/4 infections (11%), grade 4 thrombocytopenia (2%), grade 3/4 mucositis (26%), endocrinological (5%), neurologic (8%), cutaneous (3%)^{ref1, ref2}
• renal dysfunction : creatinine clearance
• 0.2-0.8 ml/sec : reduce methotrexate to 50% dose and bleomycin to 75% dose
• < 0.3 ml/sec : reduce cyclophosphamide to 50% dose
• < 0.2 ml/sec : omit methotrexate dose and reduce bleomycin to 50% dose
• hepatic dysfunction : bilirubin (mmol/l)
• 1-2X ULN : reduce doxorubicin to 50% dose and vincristine to 50% dose
• 2-4X ULN : reduce doxorubicin to 25% dose and vincristine to 25% dose
• 2-3X ULN : reduce methotrexate to 75% dose
• >3X ULN : omit methotrexate dose
• >4X ULN : omit doxorubicin dose
• neurotoxicity :
• mild motor neuropathy : reduce vincristine to 2/3 dose
• moderate motor neuropathy : reduce vincristine to 2/3 dose
• severe motor neuropathy : stop treatment with vincristine
Survival among patients treated with MACOP-B^ref, initially 76%, subsequently fell to 65%^ref.
• ProMACE-CytaBOM (prednisone 60 mg/m²/day PO days 1-14, methotrexate, doxorubicin (Adriamycin^©) 25 mg/m² IV day 1, cyclophosphamide 650 mg/m² IV day 1, etoposide 120 mg/m² IV day 1, cytarabine 300 mg/m² IV day 8, bleomycin 5 units/m² IV day 8, Oncovin^© (vincristine) 1.4 mg/m² IV day 8, methotrexate 120 mg/m² IV day 8, leucovorin calcium 25 mg/m² PO every 6 hours for 4 doses beginning 24 hours after methotrexate (i.e. days 9-12), trimethoprim/sulfamethoxazole 2 DS PO BID. Repeat cycle every 21 days for 6 cycles. Appropriate premedications. Grade 4 febrile neutropenia (20%), clinically documented infection (13%), culture-positive infection (20%), tumor lysis syndrome (16%), coagulopathy (12%), GI bleeding (5%), toxic mortality (6%), delivered dose 83%, 61% requiring RBC transfusion, hospitalization 63%, significant infectious complications (10%), Pneumocystis carinii pneumonia (PCP) (8%), platelet transfusions (7%))^{ref1, ref2} (Fisher RI, DeVita VT Jr, Hubbard SM, et al. Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 1984;3:242). Long-term survival  fell from 65% to 50% after 9 years of follow-up^ref
• ABC (Adriamycin^©, BCNU, cyclophosphamide)
• ABCD (Adriamycin^©, bleomycin, CCNU and dacarbazine)
• ABCM (Adriamycin^©, bleomycin, cyclophosphamide, mitomycin C)
• ACVBP (Adriamycin^© (doxorubicin) 75 mg/m² on day 1, cyclophosphamide 1200 mg/m² intravenously on day 1, vindesine 2 mg/m² on days 1 and 5, bleomycin 10 mg) on days 1 and 5, and prednisone 60 mg/m² orally from day 1 to day 5, and intrathecal methotrexate (15 mg) on day 2. Granulocyte-macrophage or G-CSF was administered subcutaneously on days 6 through 13 of each cycle. Repeat every 21 days for 4 courses. Patients then received a sequential consolidation therapy with 2 courses of intravenous methotrexate (3 g/m²) plus leucovorin rescue, 4 courses of etoposide (300 mg/m²) and ifosfamide (1500 mg/m²) with mesna protection, and 2 courses of mesna (100 mg/m²) subcutaneously for 4 days, each consolidation course being administered at a 14-day interval^ref)
• ABD (Adriamycin^© (doxorubicin), bleomycin, DTIC)
• ABDIC (Adriamycin^© (doxorubicin), bleomycin, dacarbazine, CCNU and prednisone)
• ABDV (Adriamycin^© (doxorubicin), bleomycin, DTIC, vinblastine)
• ABOS (Adriamycin^© (doxorubicin), bleomycin sulfate, vincristine, streptozocin)
• ABP (Adriamycin^© (doxorubicin), bleomycin, prednisone)
• ABV (actinomycin-D, bleomycin, vincristine)
• ABV (Adriamycin^© (doxorubicin), bleomycin, vinblastine)
• ABVD (Adriamycin^© (doxorubicin) 25 mg/m² i.v. at day 1 and 15, bleomycin 10 mg/m² i.v. at day 1 and 15, vincristine 6 mg/m² i.v. at day 1 and 15, dacarbazine 375 mg/m² i.v. at day 1 and 15). Repeat cycle every 28 days. Grade 3-4 neutropenia (21%), grade 3-4 neutropenic fever (2%), grade 3-4 anemia (5%), grade 3-4 infection (2%), grade 4 thrombocytopenia (5%), grade 3-4 nausea/vomiting (33%), grade 3 alopecia (24%), grade 3-4 pulmonary toxicity (6%), grade 3-4 peripheral neuropathy (1%) => death due to pulmonary toxicity (3%), > 80% of patients received full-dose doxorubicin. Emetogenic potential days 1, 15 level 5^{ref1, ref2}
• ABVd (Adriamycin^© (doxorubicin) 25 mg/m² i.v. at day 1 and 15, bleomycin 9 mg/m² (max 15 mg) i.v. at day 1 and 15, vinblastine 6 mg/m² (max 10 mg) i.v. at day 1 and 15, dacarbazine 250 mg/m² drip i.v. at day 1 and 15)^ref
• ABVE (Adriamycin^© (doxorubicin), bleomycin, vincristine, etoposide)
• ABVP (Adriamycin^© (doxorubicin), bleomycin sulfate, VM-26 / teniposide, prednisone)
• ABVP (Adriamycin^© (doxorubicin), bleomycin sulfate, vinblastine, prednisone or Adriamycin^© (doxorubicin), bleomycin sulfate, vincristine, prednisone)
• AC (Adriamycin^© (doxorubicin), carmustine)
• AC (Adriamycin^© (doxorubicin), CCNU)
• AC (Adriamycin^© (doxorubicin), cisplatin)
• Ac-D-Ac (Adriamycin^©, daunorubicin, Adriamycin^©)
• ACe (Adriamycin^© (doxorubicin), cyclophosphamide)
• ACE (Adriamycin^© (doxorubicin), cyclophosphamide, etoposide)
• ACFUCY (actinomycin-D, 5-FU, cyclophosphamide)
• ACID (Adriamycin^© (doxorubicin), cyclophosphamide, imidazole, dactinomycin)
• ACM (Adriamycin^© (doxorubicin), cyclophosphamide, methotrexate)
• ACOAP (AdriamycAdriamycin^© (doxorubicin)in^©, cyclophosphamide, Oncovin^© (vincristine), cytosine arabinoside, prednisone)
• ACOP (Adriamycin^© (doxorubicin), cyclophosphamide, Oncovin^© (vincristine), prednisone)
• ACOPP (Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), prednisone, procarbazine)
• ACT-FU-Cy (actinomycin-D, 5-FU, cyclophosphamide)
• ADBC (Adriamycin^© (doxorubicin), DTIC, bleomycin, CCNU)
• ADE (ara-C, daunorubicin, etoposide)
• ADIC (Adriamycin^©, DTIC)
• ADOC (Adriamycin^© (doxorubicin), cisplatin, vincristine, cyclophosphamide)
• AdOAP (Adriamycin^© (doxorubicin), Oncovin^© (vincristine), ara-C, prednisone)
• AdOP (Adriamycin^© (doxorubicin), Oncovin^© (vincristine), prednisone)
• Adria-L-PAM (Adriamycin^© (doxorubicin), L-phenyl-alanine mustard)
• AFM (Adriamycin^© (doxorubicin), 5-FU, methotrexate)
• AID (Adriamycin^© (doxorubicin), ifosfamide, dacarbazine, mesna)
• AIM (L-asparaginase, ifosfamide, methotrexate)
• ALOMAD (Adriamycin^© (doxorubicin), Leukeran^© (chlorambucil), Oncovin^© (vincristine), methotrexate, actinomycin-D, dacarbazine)
• AOPA (ara-C, Oncovin^© (vincristine), prednisone, L-asparaginase)
• AOPE (Adriamycin^© (doxorubicin), Oncovin^© (vincristine), prednisone, etoposide)
• APC (AMSA, prednisone, chlorambucil)
• APE (Adriamycin^©, Platinol^©Platinol^© (cisplatin), etoposide or ara-C, Platinol^© (cisplatin)^© (cisplatin), etoposide)
• APO (Adriamycin^©, prednisone, Oncovin^© (vincristine))
• ASHAP : Adriamycin^© (40 mg/m² by continuous infusion (CI) over 96 h), methylprednisolone (500 mg i.v., days 1-5), ara-C (2 g/m² as a 2-h infusion on day 5), and cisplatin (100 mg/m² by CI over 96 h)^{ref1, ref2, ref3}
• R-ASHAP : ASHAP + rituximab 375 mg/m² IV on day ^ref
• alternating triple therapy (ATT) regimen (CHOD-Bleo, ESHAP, and NOPP continued for a total of 12 cycles, 4 of each regimen)^ref

drugs	dose (mg/m2)	days	route	treatment interval (d)
CHOD-Bleo15				21
Cyclophosphamide	750	1	IV
Doxorubicin	50 (total)	1-2	IV, CI
Vincristine	1.4 (total)	1-2	IV, CI
Bleomycin	4	1	IV
Bleomycin	10 (total)	1-2	IV, CI
Dexamethasone	40 (daily)	1-4	PO
ESHAP				21
Etoposide	40 (daily)	1-4	I.V
Methylprednisolone	500 (daily)	1-5	IV
Cytarabine	2000	5	IV (2-hour infusion after platinum)
Cisplatin	100 (total)	1-4	IV, CI
NOPP				28
Mitoxantrone	10	1	IV
Vincristine	1.4	1	IV
procarbazine	100 (daily)	1-14	PO
Prednisone	100 (daily)	1-5	PO

• AV ( Adriamycin^©, vincristine)
• AVAD (doxorubicin, vincristine, cytarabine, dexamethasone)
• AVM (Adriamycin^©, vinblastine, methotrexate or Adriamycin^©, vincristine, mitomycin C)
• AVP (actinomycin-D, vincristine, Platinol^© (cisplatin) or Adriamycin^©, vincristine, procarbazine)
• BAC (BCNU, cytarabine, cyclophosphamide)
• BACO (bleomycin, Adriamycin^©, CCNU, Oncovin^©(vincristine))
• BACOD (bleomycin, Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), dexamethasone)
• BACON ( bleomycin, Adriamycin^©, CCNU, Oncovin^© (vincristine), nitrogen mustard)
• BACT (BCNU, ara-C, cyclophosphamide, thioguanine or bleomycin, Adriamycin^©, cyclophosphamide, tamoxifen)
• BAMON (bleomycin, Adriamycin^©, methotrexate, Oncovin^© (vincristine), nitrogen mustard)
• BAP (bleomycin, Adriamycin^©, prednisone)
• BAPP (bleomycin, doxorubicin, cisplatin, prednisone)
• BAVIP (bleomycin, Adriamycin^©, vinblastine, imidazole carboxamide, prednisone)
• BBVP-M (BCNU, bleomycin, VePesid^© (etoposide), prednisone, methotrexate)
• BCAP (BCNU, cyclophosphamide, Adriamycin^©, prednisone)
• BCAVe (bleomycin, CCNU,Adriamycin^©, Velban^© (vinblastine))
• BCD (bleomycin, cyclophosphamide, dactinomycin)
• B-CHOP (bleomycincyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), prednisone)
• BCMF (bleomycin, cyclophosphamide, methotrexate, 5-FU)
• BCOP (BCNU, cyclophosphamide, Oncovin^© (vincristine), prednisone)
• BCP (BCNU, cyclophosphamide, prednisone)
• BCVP (BCNU, cyclophosphamide, vincristine, prednisone)
• BCVPP (BCNU, cyclophosphamide, vinblastine, procarbazine, prednisone)
• BCVPP-bleo (BCNU, cyclophosphamide, vinblastine, procarbazine, bleomycin)
• B-DOPA ( bleomycin, dacarbazine, Oncovin^© (vincristine), prednisone, Adriamycin^©)
• BEAC (BCNU, etoposide, ara-C, cyclophosphamide)
• BEACOPP^{ref1, ref2} : the regimen is repeated on day 22
• standard dose (bleomycin 10 mg/m² day 8, etoposide 100 mg/m² days 1-3, Adriamycin^© (doxorubicin) 25 mg/m² day 1, cyclophosphamide 650 mg/m² day 1, vincristine 1.4 mg/m² (maximum 2 g) day 8, procarbazine 100 mg/m² days 1-7, prednisone 40 mg/m² days 1-14). Leukopenia grade 3 (36%) and 4 (37%), thrombocytopenia grade 3 (6%) or 4 (3%), anemia grade 3 (16%) or 4 (1%), infection grade 3 (13%) or 4 (3%), grade 3-4 mucositis (2%), respiratory tract effects (5%), nausea (12%), digestive tract effects (2%), neurologic effects (5%), skin effects (1%), pain (3%), hair loss (75%)
• increased-dose (bleomycin 10 mg/m² day 8, etoposide 200 mg/m² days 1-3, Adriamycin^© (doxorubicin) 35 mg/m² day 1, cyclophosphamide1200 mg/m² day 1, vincristine 1.4 mg/m² (maximum 2 g) day 8, procarbazine 100 mg/m² days 1-7, prednisone 40 mg/m² days 1-14). Leukopenia grade 3 (8%) and 4 (90%), thrombocytopenia grade 3 (23%) or 4 (47%), anemia grade 3 (51%) or 4 (15%), infection grade 3 (14%) or 4 (8%), grade 3-4 mucositis (8%), respiratory tract effects (4%), nausea (20%), digestive tract effects (4%), neurologic effects (4%), skin effects (4%), pain (9%), hair loss (79%)
• BEAM (BCNU 300 mg/m²_BSA i.v. for 1 day, etoposide 1200^ref mg/m²_BSA i.v. for 4 days, araC 200 mg/m²_BSA twice daily i.v. for 4 days, melphalan140 mg/m²_BSA i.v. for 1 day)

See also : ZeBEAM, miniBEAM, DexaBEAM
• BEMP (bleomycin, Eldisine^© (vindesine), mitomycin C, Platinol^©Platinol^© (cisplatin))
• BHD (BCNU, hydroxyurea (HU), dacarbazine)
• BHDV (BCNU, hydroxyurea (HU), dacarbazine, vincristine)
• BIP (bleomycin, ifosfamide, Platinol^© (cisplatin))
• BLEO-COMF (bleomycin, cyclophosphamide, Oncovin^© (vincristine), methotrexate, 5-FU)
• BLEO-MOPP (bleomycin, nitrogen mustard, Oncovin^© (vincristine), procarbazine, prednisone)
• BLEO-COMF (bleomycin, cyclophosphamide, Oncovin^© (vincristine), methotrexate, 5-FU)
• BLEO-MOPP (bleomycin, nitrogen mustard, Oncovin^© (vincristine), procarbazine, prednisone)
• BOAP (bleomycin, Oncovin^© (vincristine), Adriamycin^©, prednisone)
• BOLD (bleomycin, Oncovin^© (vincristine), lomustine, dacarbazine)
• BOMES (BCNU, vincristine, methotrexate, etoposide, and methylprednisolone)
• BOMP (bleomycin, Oncovin^© (vincristine), Matulane^© (procarbazine), prednisone)
• BONP (bleomycin, Oncovin^© (vincristine), Natulan^© (procarbazine), prednisolone)
• BOP (BCNU, Oncovin^© (vincristine), prednisone)
• BOP (bleomycin, Oncovin^© (vincristine), Platinol^© (cisplatin))
• BOPAM (bleomycin, Oncovin^© (vincristine), prednisone, Adriamycin^©, mechlorethamine, methotrexate)
• BOPP (BCNU, Oncovin^© (vincristine), procarbazine, prednisone)
• BR : bendamustine 90 mg/m² as a 30-minute infusion on days 1 and 2, rituximab 375 mg/m² IV on day 1, for a maximum of 4 cycles every 4 weeks^ref
• BuCy (busulfan, cyclophosphamide)
• BuEtoposide (etoposide)
• BVAC : high-dose carmustine 600 mg/m², etoposide 1600 mg/m², cytarabine 24 g/m², and cyclophosphamide 90 mg/kg
• BVAP (BCNU, vincristine, Adriamycin^©, prednisone)
• BVCPP (BCNU, vinblastine, cyclophosphamide, procarbazine, prednisone)
• BVD (BCNU, vincristine, dacarbazine)
• BVDS (bleomycin, Velban^© (vinblastine), doxorubicin, streptozocin)
• BVPP (BCNU, vincristine, procarbazine, prednisone)
• CA (cyclophosphamide, Adriamycin^©)
• CABOP, CA-BOP (cyclophosphamide, Adriamycin^©, bleomycin, Oncovin^© (vincristine), prednisone)
• CABS (BCNU, Adriamycin^©, bleomycin, streptozocin)
• CAC (cisplatin, ara-C, caffeine)
• CAD (cyclophosphamide, Adriamycin^©, dacarbazine OR cytosine arabinoside, daunorubicin OR cyclophosphamide, Adriamycin^©, dexamethasone)
• CADIC ( cyclophosphamide, Adriamycin^©, DTIC )
• CAE (cyclophosphamide, Adriamycin^©, etoposide)
• CAF (cyclophosphamide, Adriamycin^©, 5-FU)
• CAFFI (cyclophosphamide, Adriamycin^©, 5-FU by continuous infusion)
• CAFP (cyclophosphamide, Adriamycin^©, 5-FU, prednisone)
• CAFTH (cyclophosphamide, Adriamycin^©, 5-FU, tamoxifen, Halotestin^© (fluoxymesterone))
• CAFVP (cyclophosphamide, Adriamycin^©, 5-FU, vincristine, prednisone)
• CAG (cytosine arabinoside, aclacinomycin, and G-CSF)
• CALF (cyclophosphamide, Adriamycin^©, leucovorin calcium, 5-FU)
• CALF-E (cyclophosphamide, Adriamycin^©, leucovorin calcium, 5-FU, ethinyl estradiol)
• CAM (cyclophosphamide, Adriamycin^©, methotrexate)
• CAMB (cyclophosphamide, Adriamycin^©, methotrexate, bleomycin)
• CAMELEON (cytosine arabinoside, high-dose methotrexate, leucovorin calcium, Oncovin^© (vincristine))
• CAMEO (cyclophosphamide, Adriamycin^©, methotrexate, etoposide, Oncovin^© (vincristine))
• CAMF (cyclophosphamide, Adriamycin^©, methotrexate, 5-FU or cyclophosphamide, Adriamycin^©methotrexate, leucovorin / folinic acid calcium)
• CAMLO (cytosine arabinoside, methotrexate, leucovorin calcium, Oncovin^© (vincristine))
• CAMP (cyclophosphamide, Adriamycin^©, methotrexate, procarbazine)
• CAO (cyclophosphamide, Adriamycin^©, Oncovin^© (vincristine))
• CAP (cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin) or cyclophosphamide, Adriamycin^©, prednisone)
• CAP-I (cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• CAP-II (cyclophosphamide, Adriamycin^©, high-dose Platinol^© (cisplatin))
• CAP-BOP (cyclophosphamide, Adriamycin^©, procarbazine, bleomycin, Oncovin^© (vincristine), prednisone)
• CAPPr (cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin), prednisone)
• CAT (cytosine arabinoside, Adriamycin^©, thioguanine or cytosine arabinoside, thioguanine)
• CAV (cyclophosphamide, Adriamycin^©, Velban^© (vinblastine) or cyclophosphamide, Adriamycin^©, vincristine)
• CAVe, CA-Ve (CCNU, Adriamycin^©, Velban^© (vinblastine))
• CAVP (cyclophosphamide, Adriamycin^©, VM-26 / teniposide, prednisone)
• CAVP-I (cyclophosphamide, Adriamycin^©, vincristine, prednisone)
• CAVP-16 (cyclophosphamide, Adriamycin^©, VP-16)
• CAVPM (cyclophosphamide, Adriamycin^©, VP-16, prednisone, methotrexate)
• CPBBA (cyclophosphamide, bleomycin, procarbazine, prednisone, Adriamycin^©)
• CBV (cyclophosphamide 1.5-1.8 g/m² i.v. for 4 days, BCNU 300-600 mg/m² i.v. for 1 day, VP-16 150-400 mg/m² twice day i.v. for 4 days)
• CBVD (CCNU, bleomycin, vinblastine, dexamethasone)
• CC (carboplatin, cyclophosphamide)
• CCAVV (CCNU, cyclophosphamide, Adriamycin^©, vincristine, VP-16)
• CCFE (cyclophosphamide, cisplatin, 5-FU, estramustine)
• CCM (cyclophosphamide, CCNU, methotrexate)
• CCMA (CCNU, cyclophosphamide, methotrexate, Adriamycin^©)
• CCNU-OP (CCNU, Oncovin^© (vincristine), prednisone)
• CCOB (CCNU, cyclophosphamide, Oncovin^© (vincristine), bleomycin)
• CCV (CCNU, cyclophosphamide, vincristine)
• CCV-AV (CCNU, cyclophosphamide, vincristine/Adriamycin^©, vincristine)
• CCVB (CCNU, cyclophosphamide, vincristine, bleomycin)
• CCVPP (CCNU, cyclophosphamide, Velban^© (vinblastine), procarbazine, prednisone)
• CCVV (cyclophosphamide, CCNU, VP-16, vincristine)
• CCVVP (cyclophosphamide, CCNU, VP-16, vincristine, Platinol^© (cisplatin))
• CD (cytarabine, daunorubicin)
• CDC (carboplatin, doxorubicin, cyclophosphamide)
• CDE (cyclophosphamide 200 mg/m²/day IV continuous infusion days 1-4, doxorubicin 12.5 mg/m²/day IV continuous infusion days 1-4, etoposide 60 mg/m²/day IV continuous infusion days 1-4. With filgrastim 5 mg/kg/day subcutaneously starting 24 hours following completion of chemotherapy until postnadir neutrophil count >= 10,000/ml; resume if neutrophil count < 1,500/ml prior to next cycle. CNS prophylaxis given with intratechal cytarabine 50 mg days 1, 4 in cycles 1 and 2 for patients with small noncleaved-cell lymphoma or lymphomatous bone marrow involvement. Patients with meningeal lymphoma at diagnosis given whole brain radiotherapy (see article) plus intratechal cytarabine 50 mg alternating with methotrexate 10 mg/m² to maximum 15 mg 3 times weekly until CSF cytology negative on 2 consecutive occasions, then twice weekly for 2 weeks, then weekly for 4 weeks. Repeat cycle every 28 weeks. All patients received highly active antiretroviral therapy. Patients received infection prophylaxis with fluconazole 100 mg PO daily, trimethoprim/sulfamethoxazole 160/800 mg PO 3 times a week. Optional infection prophylaxis included rifabutin 300 mg PO daily (if CD4 count < 75/ml) and ciprofloxacin 500 mg PO twice daily on day 6 until neutrophil recovery. Leukopenia grade 3 (28%) or 4 (59%), neutropenia grade 3 (17%) or 4 (73%), anemia grade 1-2 (43%), 3 (45%) or 4 (9%), grade 3 fever (43%), infection (20%), thrombocytopenia (54%), grade 3 stomatitis (11%), metabolic (17%), liver (14%), nausea (9%), diarrhea (8%), vomiting (8%), neuromotor (7%), pulmonary (6%), weight gain (6%) o loss (5%), neuropsychologic (3%), cardiac (2%), hypertension (2%), hypotension (2%), skin (2%). Emetogenic potential days 1-4 level 5)^ref
• CEB (carboplatin, etoposide, bleomycin)
• CECA (cisplatin, etoposide, cyclophosphamide, Adriamycin^©)
• CEF (cyclophosphamide, epirubicin, 5-FU)
• CEM (cytosine arabinoside, etoposide, methotrexate)
• CEP (CCNU, etoposide, prednimustine)
• CEP (cyclophosphamide, etoposide, Platinol^© (cisplatin))
• CEV (cyclophosphamide, etoposide, vincristine)
• CF (cisplatin, 5-FU)
• CFL (cisplatin, 5-FU, leucovorin calcium)
• CFM (cyclophosphamide, 5-FU, mitoxantrone)
• CFP (cyclophosphamide, 5-FU, prednisone)
• CFPT (cyclophosphamide, 5-FU, prednisone, tamoxifen)
• CHAD (cyclophosphamide, hexamethylmelamine, Adriamycin^©, DDP)
• CHAMOCA (cyclophosphamide, hydroxyurea (HU), actinomycin-D, methotrexate, Oncovin^© (vincristine), leucovorin calcium, Adriamycin^©)
• CH1VPP, Ch1VPP (chlorambucil, vinblastine, procarbazine, prednisone)
• CHAP (cyclophosphamide, Hexalen^© (hexamethylmelamine), Adriamycin^©, Platinol^© (cisplatin))
• CHD (cyclophosphamide, hexamethylmelamine, DDP)
• CHD-R (cyclophosphamide, hexamethylmelamine, DDP, radiotherapy)
• CHEX-UP (cyclophosphamide, hexamethylmelamine, 5-FU, Platinol^© (cisplatin))
• CHF (cyclophosphamide, hexamethylmelamine, 5-FU)
• Chl-VPP (chlorambucil 6 mg/m²/day PO days 1-14, maximum 10 mg/day, vinblastine 6 mg/m² IV days 1, 8, maximum 10 mg/day, procarbazine 100 mg/m²/day PO days 1-14, maximum 150 mg/day, prednisone 40 mg/day PO days 1-14. Repeat cycle every 28 days. Leukopenia grade 3 (7%) or 4 (2%), anemia grade 1 (20%) or 2 (9%), grade 3-4 infection (3%), thrombocytopenia (5%), nausea/vomiting (2%) => dose delayed 1 week in 31% of patients. Dose delayed 2 weeks in 33% of patients. Emetogenic potential days 1-14 level 4^ref.
• CHO (cyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine))
• CHOB (cyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), bleomycin)
• CHOD (cyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), dexamethasone)
• CHOD-Bleo : CHOD + bleomycin
• CHOP-BLEO (cyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), prednisone, bleomycin)
• CHOP-DI (CHOP dose-intensified : cyclophosphamide 1,600 mg/m² IV day 1, doxorubicin65 mg/m² IV day 1, and Oncovin^© (vincristine) 1.4 mg/m² IV day 1, prednisone 100 mg/day PO days 1-5, filgrastim 5 mg/kg/day subcutaneously from day 2 for 10 days or until ANC > 10,000 cells/mm³. Repeat cycle every 14 days. Treatment administered in an outpatient setting. Leukopenia grade 3 (6%) or 4 (88%), neutropenia grade 3 (9%) or 4 (86%), anemia grade 0 (8%), 1 (10%), 2 (26%), 3 (50%) or 4 (9%) grade 3-5 infection (20%), grade 3-5 respiratory infection (9%), thrombocytopenia (43%), stomatitis (15%), grade 3 paresthesia (6%), grade 3 nausea (5%), diarrhea (4%), hemorrhagic cystitis (4%), vomiting (4%), grade 3 cardiac, EF/CHF (3%), grade 3-5 dysrhythmia (3%) => the mean delivered dose intensity for all cytotoxic drugs was 1.80 compared to standard CHOP dosing. There were 3 treatment related deaths due to myelosuppression. Emetogenic potential day 1 level 5)^ref
• CHOR (cyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), radiotherapy)
• CIP : cisplatin 50 mg/m² on day 1, prednisone 25 mg on days 1-14 and idarubicin 15 mg/m² on day 8
• CISCA : cisplatin, cyclophosphamide, and doxorubicin
• CISCA/VB : CISCA alternating with vinblastine and bleomycin
• CISCAii/BViv (cisplatin, cyclophosphamide, Adriamycin^©, vinblastine, bleomycin)
• CIVPP (chlorambucil, vinblastine, procarbazine, prednisone)
• CLAG : cladribine, cytarabine and G-CSF^ref
• CMC (cyclophosphamide, methotrexate, CCNU)
• CMC-VAP (cyclophosphamide, methotrexate, CCNU, vincristine, Adriamycin^©, procarbazine)
• CMF (cyclophosphamide, methotrexate, 5-FU)
• CMF-AV (cyclophosphamide, methotrexate, 5-FU, Adriamycin^©, vincristine)
• CMFAVP (cyclophosphamide, methotrexate, 5-FU, Adriamycin^©, vincristine, prednisone)
• CMF-BLEO (cyclophosphamide, methotrexate, 5-FU, bleomycin)
• CMF-FLU (cyclophosphamide, methotrexate, 5-FU, fluoxymesterone)
• CMFH (cyclophosphamide, methotrexate, 5-FU, hydroxyurea (HU))
• CMFP (cyclophosphamide, methotrexate, 5-FU,prednisone)
• CMFPT (cyclophosphamide, methotrexate, 5-FU, prednisone, tamoxifen)
• CMFPTH (cyclophosphamide, methotrexate, 5-FU, prednisone, tamoxifen, Halotestin^© (fluoxymesterone))
• CMFP-VA (cyclophosphamide, methotrexate, 5-FU, prednisone, vincristine, Adriamycin^©)
• CMFT (cyclophosphamide, methotrexate, 5-FU, tamoxifen)
• CMF-TAM (cyclophosphamide, methotrexate, 5-FU, tamoxifen)
• CM-5-FU (cyclophosphamide, methotrexate, 5-FU)
• CMFV (cyclophosphamide, methotrexate, 5-FU, vincristine)
• CMFVAT (cyclophosphamide, methotrexate, 5-FU, vincristine, Adriamycin^©, testosterone)
• CMFVP (cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone)
• CMH (cyclophosphamide, m-AMSA, hydroxyurea (HU))
• CMOPP, C-MOPP (cyclophosphamide, mechlorethamine, Oncovin^© (vincristine), procarbazine, prednisone)^ref
• CMP (CCNU, methotrexate, procarbazine)
• CMPF (cyclophosphamide, methotrexate, prednisone, 5-FU)
• CMV : cisplatin, methotrexate, and vinblastine
• CNF (cyclophosphamide, Novantrone^©, 5-FU)
• CNOP, C-NOP (cyclophosphamide 750 m/m² IV day 1, Novantrone^© (mitoxantrone) 10 mg/m² IV day 1, Oncovin^© (vincristine) 1.4 mg/m² IV day 1, prednisone 50 mg/m²/day PO days 1-5. Repeat cycle every 21 days. Grade 4 neutropenia (91%), grade 4 febrile neutropenia (47%), grade 3-4 stomatitis (2%), mucositis (2%), alopecia (24%), nausea/vomiting (16%), neurologic (7%), cardiac (2%), cutaneous (2%), diarrhea (2%) => infectious mortality (11%), hospitalization for neutropenic fever (48%). Emetogenic potential day 1 level 4)^ref
• COAP (cyclophosphamide, Oncovin^© (vincristine), ara-C, prednisone)
• COAP-BLEO (cyclophosphamide, Oncovin^© (vincristine), ara-C, prednisone, bleomycin)
• COB (cisplatin, Oncovin^© (vincristine), bleomycin)
• COBMAM (cyclophosphamide, Oncovin^© (vincristine), bleomycin, methotrexate, Adriamycin^©, MeCCNU)
• CODOX-M (cyclophosphamide 800 mg/m² IV day 1, then 200 mg/m²/day IV days 2-5, Oncovin^© (vincristine) 1.5 mg/m² (maximum 2 mg) IV days 1, 8 in cycle 1 and days 1, 8, 15 in cycle 3, doxorubicin 40 mg/m² IV day 1, cytarabine intratechal 70 mg days 1, 3, high-dose methotrexate 1200 mg/m² IV over 1 hour followed by 240 mg/m²/hour for the next 23 hours starting day 10, leucovorin 192 mg/m² IV to start 12 hours after the completion of the methotrexate infusion for 1 dose, then 12 mg/m² IV every 6 hours until the methotrexate level is < 5 x 10^-8 mol/L. GM-CSF 7.5 mg/kg/day or G-CSF 1 fl SC subcutaneously day 13 onward until ANC > 1000, methotrexate 12 mg intratechal day 15 with folic acid rescue. Patients with CNS disease at presentation received intratechal therapy during the first CODOX-M cycle with intratechal cytarabine day 5 and intratechal methotrexate 495 mg/m² iv day 4 with folic acid rescue day 4 (day 17 ?). Regimen consists of alternating cycles of CODOX-M and IVAC for a total of 4 cycles. Neutropenia grade 4 (98%), leukepenia grade 4 (96-98%), grade 3-4 thrombocytopenia (71% < 18 years; 49% > 18 years), stomatitis (69% < 18 years; 49% >= 18 years), hepatotoxicity (27%) => infections in 47% of cycles, sepsis in 22% of cycles, average duration of neutropenia 12 days (range 0-22), 11 patients developed a profound neuropathy. Emetogenic potential day 1 level 5, days 2-5 level 2, day 8 level 1, day 10 level 4)^{ref1, ref2}
• COF/COM (cyclophosphamide, Oncovin^© (vincristine), 5-FU/cyclophosphamide, Oncovin^© (vincristine), methotrexate)
• COM (cyclophosphamide, Oncovin^© (vincristine), methotrexate or cyclophosphamide, Oncovin^© (vincristine), MeCCNU)
• COMA-A (cyclophosphamide, Oncovin^© (vincristine), methotrexate, Adriamycin^©, ara-C)
• COMB (cyclophosphamide, Oncovin^© (vincristine), methotrexate, bleomycin or cyclophosphamide, Oncovin^© (vincristine), MeCCNU, bleomycin)
• COMBAP (cyclophosphamide, Oncovin^© (vincristine), methotrexate, bleomycin, Adriamycin^©, prednisone)
• COMe (cyclophosphamide, Oncovin^© (vincristine), methotrexate)
• COMET-A (cyclophosphamide, Oncovin^© (vincristine), methotrexate, leucovorin / folinic acid calcium, etoposide, ara-c)
• COMF (cyclophosphamide, Oncovin^© (vincristine), methotrexate, 5-FU)
• COMLA (cyclophosphamide, Oncovin^© (vincristine), methotrexate, leucovorin / folinic acid calcium, ara-C)
• COMP (cyclophosphamide, Oncovin^© (vincristine), methotrexate, prednisone)
• CONPADRI, COPADRI-I (cyclophosphamide, Oncovin^© (vincristine), L-phenyl-alanine mustard, Adriamycin^©)
• Cooper CMFVP (cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone)
• Cooper Regimen (cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone)
• COP (cyclophosphamide, Oncovin^© (vincristine), prednisone or cyclophosphamide, Oncovin^© (vincristine), prednisolone)
• COPA (cyclophosphamide, Oncovin^© (vincristine), prednisone, Adriamycin^©)
• COPA-BLEO (cyclophosphamide, Oncovin^© (vincristine), prednisone, Adriamycin^©, bleomycin)
• COPAC (CCNU, Oncovin^© (vincristine), prednisone, Adriamycin^©, cyclophosphamide)
• COP-B, COPB (cyclophosphamide, Oncovin^© (vincristine), prednisone, bleomycin)
• COP-BLEO (cyclophosphamide, Oncovin^© (vincristine), prednisone, bleomycin)
• COPE (cyclophosphamide, Oncovin^© (vincristine), Platinol^© (cisplatin), etoposide)
• CP
• cyclophosphamide, Platinol^© (cisplatin)
• cyclophosphamide, prednisone
• chlorambucil 0.3 mg/kg (or 10 mg/m²) PO days 1-5, prednisone 25-40 mg/m² PO days 1-5. Repeat cycle every 28 days^ref
• CPB (cyclophosphamide, Platinol^© (cisplatin), BCNU)
• CPC (cyclophosphamide, Platinol^© (cisplatin), carboplatin)
• CPM (CCNU, procarbazine, methotrexate)
• CPOB (cyclophosphamide, prednisone, Oncovin^© (vincristine), bleomycin)
• CROP (cyclophosphamide, Rubidazone^© (zorubicin), Oncovin^© (vincristine), prednisone)
• CROPAM (cyclophosphamide, Rubidazone^© (zorubicin), Oncovin^© (vincristine), prednisone, L-asparaginase, methotrexate)
• CT (cytarabine, thioguanine)
• CTCb (cyclophosphamide, thiotepa, carboplatin)
• CTX-Plat (cyclophosphamide, Platinol^© (cisplatin))
• CV (cisplatin, VP-16)
• CVA (cyclophosphamide, vincristine, Adriamycin^©)
• CVA-BMP (cyclophosphamide, vincristine, Adriamycin^©, BCNU, methotrexate, procarbazine)
• CVAMP (cyclophosphamide, vincristine, Adriamycin^©, methyl-prednisolone)
• C-VAD, CVAD (cyclophosphamide, vincristine, Adriamycin^©, dexamethasone)
• hyper-CVAD : hyperfractionated CVAD, a dose-intensive chemotherapy regimen in adult acute lymphocytic leukemia (ALL)^ref, Burkitt's lymphoma^ref, lymphoblastic lymphoma, mantle cell lymphoma, and multiple myeloma.
• hyper-CVAD/M-A : 4 courses of fractionated cyclophosphamide 1,800 mg/m² administered with doxorubicin (Adriamycin^©), vincristine, and dexamethasone (Hyper-CVAD) that alternated with high-dose methotrexate and cytarabine^ref
• R-hyper-CVAD : hyper-CVAD + rituximab 375 mg/m² IV on day 1
• R-hyper-CVAD/M-A : R-hyper-CVADalternating with rituximab plus high-dose methotrexate and cytarabine^ref
• course A : cyclophosphamide 300 mg/m² i.v. day 1 to 3 q12h x 6 doses, vincristine 2 mg i.v. on days 5 and 11 12h after last cyclophosphamide dose, doxorubicin (Adriamycin^©) 50 mg/m² i.v. continuous infusion 12 h after last cyclophosphamide dose at days 4 and 5, dexamethasone 40 mg/m² day i.v. or p.o. at days 1 to 4 and 11 to 14
• course B (to begin immediately after hematologic recovery from course A) : methotrexate 200 mg/m² i.v. on day 1 followed by 800 mg/m² i.v. continuous infusion over 24 h, cytarabine 3 mg/m² IV q12h for 4 doses on days 2 and 3
• CVB : CCNU, vinblastine, bleomycin OR cyclophosphamide, CCNU, etoposide^ef
• CVBD (CCNU, vinblastine, bleomycin, dexamethasone)
• CVD (cisplatin, vinblastine, dacarbazine)
• CVEB (cisplatin, Velban^© (vinblastine), etoposide, bleomycin)
• CVI (carboplatin, VePesid^© (etoposide), ifosfamide, mesna)
• CVM (cyclophosphamide, vincristine, methotrexate)
• CVP (cyclophosphamide 400 mg/m² IV on days 1-5, vincristine 1.4 mg/m² (maximum 2 mg) IV day 1, prednisone 40 mg/m² PO day 1-5). Repeat every 21 days for 6 cycles
• R-CVP : CVP + rituximab 375 mg/m² IV on day 5
• CVP-BLEO (CVP + bleomycin)
• CVPP (CCNU, vinblastine, prednisone, procarbazine)
• CVPP (cyclophosphamide, vinblastine, procarbazine, prednisone)
• CVPP-CCNU (cyclophosphamide, vinblastine, procarbazine, prednisone, CCNU)
• CyADIC (cyclophosphamide, Adriamycin^©, DTIC)
• CyHOP (cyclophosphamide, Halotestin^© (fluoxymesterone), Oncovin^© (vincristine), prednisone)
• CytaBOM, CYTABOM (cytarabine, bleomycin, Oncovin^© (vincristine), mechlorethamine)
• CyVADACT, CY-VA-DACT (cyclophosphamide, vincristine, Adriamycin^©, dactinomycin)
• CyVADIC (cyclophosphamide, vincristine, methotrexate, Adriamycin^©, DTIC)
• CyVMAD (cyclophosphamide, vincristine, methotrexate, Adriamycin^©, DTIC)
• DA-EPOCH (dose-adjusted EPOCH)
• DAP (dianhydrogalactitol, Adriamycin^©, Platinol^© (cisplatin))
• DAP/TMP (dapsone, trimethoprim)
• DAT (daunomycin, ara-C, thioguanine)
• DATE (daunorubicin 1,5 mg/Kg on day 1, ara-C 1,5 mg/Kg q12h for 5 days, thioguanine 1,5 mg/kg q12h for 5 days, etoposide 1,5 mg/Kg q12h since day 6 to day 10)
• DATVP (daunomycin, ara-C, thioguanine, vincristine, prednisone)
• DAV :
• dibromodulcitol, Adriamycin^©, vincristine
• vincristine 0.4 mg/day IV continuous infusion days 1-4, doxorubicin (Adriamycin^©) 9 mg/m²/day IV continuous infusion days 1-4, dexamethasone 40 mg PO days 1-4, 9-12, 17-20. Repeat cycle every 28-35 days. Neutropenia grade 3 (15%), sepsis (30%), thrombocytopenia grade >= 2 (11%), infectious mortality (2%), sepsis (30%), catheter thrombus/infection (14%), cushingoid features (26%), diabetes requiring insulin (11%). Emetogenic potential days 1-4 level 2^ref) (see also VAD)
• DAVA (desacetyl vinblastine amide)
• DAVH (dibromodulcitol, Adriamycin^©, vincristine, Halotestin^© (fluoxymesterone))
• DBV (dacarbazine, BCNU, vincristine)
• DC (daunorubicin, cytarabine)
• DCCMP (daunorubicin, cyclocytidine, 6-metacaptopurine, prednisone)
•  DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin)
• VAD-DCEP
• DCM (dichloromethotrexate)
• DCMP (daunorubicin, cytarabine, 6-metacaptopurine, prednisone)
• DCT (daunorubicin, cytarabine, thioguanine)
• DCV (dacarbazine, CCNU, vincristine)
• DECAL (dexamethasone, etoposide, cisplatin, ara-C, L-asparaginase)
• DexaBEAM : dexamethasone + BEAM^{ref1, ref2, ref3}
• DFV (DDP, 5-FU, VePesid^© (etoposide))
• DHAOx : dexamethasone 40 mg/day PO or IV days 1-4, high-dose ara-C 2000 mg/m² IV every 12 hours for 2 doses, day 2, oxaliplatin
• DHAP (dexamethasone 40 mg/day PO or IV days 1-4, high-dose ara-C 2000 mg/m² IV every 12 hours for 2 doses, day 2, Platinol^© (cisplatin) 100 mg/m²/day IV continuous infusion day 1. Grade 4 neutropenia (53%), neutropenic infection (31%), grade 4 thrombocytopenia (39%), gastrointestinal (20%), renal (Scr > double baseline : 20%), neurological (6%), respiratory (6%), tumor lysis syndrome (5%) => infectious mortality (11%), hospitalization for neutropenic fever (48%), mortality due to tumor lysis syndrome (3%). Emetogenic potential day 1 level 5, day 2 level 4)^ref
• DICE (dexamethasone, ifosfamide, carboplatin, and etoposide)
• DICEP : dose-intensive cyclophosphamide 5.25 g/m², etoposide 1.05 g/m², cisplatin 105 mg/m² (DICEP) for tumor cytoreduction and HSC mobilization^{ref1, ref2}
• DL (doxorubicin, lomustine)
• DMC (dactinomycin, methotrexate, cyclophosphamide)
• DMVM (doxorubicin, methotrexate, vinblastine and methylprednisolone)
• DOAP (daunorubicin, Oncovin^© (vincristine), ara-C, prednisone)
• DTIC-ACTD (DTIC, actinomycin-D)
• DT-PACE : dexamethasone 40 mg PO daily for 4 days, thalidomide 400 mg PO daily at night,  4 days of IV continuous-infusion cisplatin 10 mg/m²/day, doxorubicin 10 mg/m²/day, cyclophosphamide 400 mg/m²/day, and etoposide 40 mg/m²/day. Repeated at 4- to 6-week intervals. Grade 3-4 ANC < 1.5 x 109/L (65%), < 0.5 x 109/l (39%), neutropenic fever (12%), documented infection (ANC < 1.0 x 10⁹/l) (4%), stomatitis/pharyngitis (4%), esophagitis/gastritis (2%), nausea/vomiting (6%), thromboembolism (5%), hypophosphatemia (4%), sensory neuropathy (4%), colitis (3%), hypocalcemia (3%), ataxia (2%), diarrhea (2%), hypoalbuminemia (2%), hypokalemia (2%), supraventricular arrhythmia (2%), syncope (2%), CHF (1%), decrease in bicarbonate (1%), dyspnea (1%), erythema/rash (1%), hyperbilirubinemia (1%), hypomagnesemia (1%), hyponatremia (1%), hypotension (1%), pulmonary edema (1%), seizure (1%), sinus bradycardia (1%) => 4% treatment-related mortality at 3 months after second cycle, 3 cases of nonfatal pulmonary embolism. Emetogenic potential days 1-4 level 5^ref
• DVB (DDP, vindesine, bleomycin)
• DVP (daunorubicin, vincristine, prednisone)
• DVPL-ASP (daunorubicin, vincristine, prednisone, L-asparaginase)
• DZAPO (daunorubicin, azacitidine, ara-C, prednisone, Oncovin^© (vincristine))
• EAP (etoposide, Adriamycin^©, Platinol^© (cisplatin))
• EBAP (Eldisine^© (vindesine), BCNU, Adriamycin^©, prednisone)
• ECF (epirubicin, CDDP, 5-FU)
• ECHO (etoposide, cyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine))
• ECMV (etoposide, cyclophosphamide, methotrexate, vincristine)
• EDAM (10-ethyl-deaza-aminopterin or 10-EdAM)
• EDAP (etoposide, dexamethasone, ara-C, Platinol^© (cisplatin))
• EFP (etoposide, 5-FU, Platinol^© (cisplatin))
• ELF (etoposide, leucovorin / folinic acid calcium, 5-FU)
• EMA : timed sequential chemotherapy including a first sequence combining mitoxantrone (12 mg/m² per day over 3 days) with cytarabine (500 mg/m² per day over the same period), and a second sequence consisting in etoposide (200 mg/m² per day for 3 days) and cytarabine as in the first sequence, has been proposed as a salvage regimen for relapsed AML^ref
• EMACO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, Oncovin^© (vincristine))
• E-MVAC (escalated methotrexate, vinblastine, Adriamycin^©, cyclophosphamide)
• EP (etoposide, Platinol^© (cisplatin))
• epi-ADR (epinephrine-Adriamycin^©)
• EPiC : first and third cycles consisted of cyclophosphamide (4 gm/m²) and carboplatin (400 mg/m²). Second and fourth cycles consisted of carboplatin (1 gm/m²), and etoposide (450 mg/m²)^ref
• EPOCH (etoposide, prednisone, Oncovin^© (vincristine), cyclophosphamide, Halotestin^©(fluoxymesterone) or etoposide, prednisone, Oncovin^© (vincristine) + doxorubicin)

drug	dose	route	treatment days
infused agents (mixed in the same solution) :
etoposide	50 mg/m2/day	CIV	1, 2, 3, 4 (96 hours)
doxorubicin	10 mg/m2/day	CIV	1, 2, 3, 4 (96 hours)
Oncovin© (vincristine) (dose never routinely capped) :	0.4 mg/m2/day	CIV	1, 2, 3, 4 (96 hours)
bolus agents
cyclophosphamide	750 mg/m2/day	IV	5
prednisone	60 mg/m2/bid	Oral	1, 2, 3, 4, 5
G-CSF	5 µg/kg/day	SC	6 to ANC > 5 × 109/L past nadir
next cycle (began on day 21 if the ANC was at least 1 × 109/L and the platelet count was at least 100 × 109/L)			Day 21

EPOCH dose-adjustment paradigm :

nadir measurements (measurements of ANC and platelet nadir are based on twice weekly CBC only)	dose-adjustment (dose adjustments above starting dose level (level 1) apply to etoposide, doxorubicin and cyclophosphamide. Dose adjustments below starting dose level (level 1) apply to cyclophosphamide only. )
if nadir ANC at least 0.5 × 109/L	20% increase in etoposide, doxorubicin, and cyclophosphamide above last cycle
if nadir ANC less than 0.5 × 109/L on 1 or 2 measurements	same dose(s) as last cycle
if nadir ANC less than 0.5 × 109/L on at least 3 measurements	20% decrease in etoposide, doxorubicin, and cyclophosphamide below last cycle
if nadir platelet count < 25 × 109/L on 1 measurement	20% decrease in etoposide, doxorubicin, and cyclophosphamide below last cycle

All patients received G-CSF beginning on day 6 and continued until the ANC was more than 5 × 10⁹/L above the nadir level. To prevent Pneumocystis carinii pneumonia, patients received sulfamethoxazole-trimethoprim twice daily for 3 days per week. Cycles were begun every 21 days, providing that the ANC was at least 1 × 109/L and the platelet count was at least 100 × 10⁹/L. If the values were below these levels, counts were checked daily until recovery and G-CSF was administered as indicated. Dose adjustments are a fundamental component of the EPOCH regimen. Adjustments above the starting-dose level always applied to etoposide, doxorubicin, and cyclophosphamide; and adjustments below the starting-dose level applied only to cyclophosphamide. All drug doses were based on true body weight. The adjustment paradigm was based on the ANC nadir in the previous cycle and was designed to achieve a shallow period of neutropenia. If a platelet nadir value below 25 × 10⁹/L was observed, doses were reduced only 20%, regardless of the ANC nadir. The adjustment paradigm was based specifically on twice-weekly complete blood counts obtained 3 days apart, such as Monday and Thursday or Tuesday and Friday, and was not intended to identify every neutropenic event. For example, if the lowest ANC was 0.5 × 10⁹/L, doses were escalated irrespective of whether the physician thought the patient had a lower nadir on a day on which an ANC was not done. Deviations from the adjustment paradigm were made only rarely in the event of a critical illness during the previous cycle and not for uncomplicated infections. Vincristine was administered at a fixed dose of 1.6 mg/m² of body-surface area (0.4 mg/m² per day), and the dose was never capped. The vincristine dose was reduced 25% if grade 2 motor neuropathy developed, 50% for grade 3 motor neuropathy, and 50% for grade 3 sensory neuropathy. Common side effects such as moderate constipation and sensory neuropathy were managed aggressively, without routine reductions in the dose of vincristine. Severe constipation was more frequent during the first cycle and decreased substantially during subsequent cycles. The dose of vincristine was increased up to a full dose if the toxic effect for which it had been reduced lessened^ref.
• EPOCH-R (etoposide, prednisone, Oncovin^© (vincristine) + doxorubicin + rituximab)
• ESHAP (etoposide 40 mg/m²/day IV days 1-4, Solu-Medrol (methylprednisolone) 250-500 mg/day IV days 1-5, ara-C 2000 mg/m² IV day 5 (give immediately following completion of etoposide and cisplatin), Platinol^© (cisplatin) 25 mg/m²/day IV continuos infusion days 1-4 (total 100 mg/m²). Repeat cycle every 21-28 days. Grade 3-4 febrile neutropenia (30%), renal (SCr > double baseline) (22%), grade 3 nausea/vomiting (6%) => infectious mortality (4%), hospitalization (30%), permanent renal toxicity (4%))^ref
• MINE–ESHAP (mesna, ifosfamide, Novantrone^© (mitoxantrone), etoposide, ESHAP)
• EVA (etoposide, vinblastine, Adriamycin^©)
• EVMAC (escalated methotrexate, vinblastine, Adriamycin^©, cisplatin)
• FAC (5-FU, Adriamycin^©, cyclophosphamide)
• FAC-BCG (ftorafur, Adriamycin^©, cyclophosphamide, BCG)
• FAC-LEV (5-FU, Adriamycin^©, cyclophosphamide, levamisole)
• FAC-M (5-FU, Adriamycin^©, cyclophosphamide, methotrexate)
• FACP (ftorafur, Adriamycin^©, cyclophosphamide, Platinol^© (cisplatin))
• FACS (5-FU, Adriamycin^©, cyclophosphamide, streptozocin)
• FACVP (5-FU, Adriamycin^©, cyclophosphamide, VP-16)
• FAM : 5-FU, Adriamycin^©, and mitomycin C
• FAM-C (5-FU, Adriamycin^©, MeCCNU)
• FAM-CF (5-FU, Adriamycin^©, mitomycin C, citrovorum factor)
• FAME, FAMe (5-FU, Adriamycin^©, MeCCNU)
• FAMMe (5-FU, Adriamycin^©, mitomycin C, MeCCNU)
• FAMP (fludarabine monophosphate)
• FAM-S (5-FU, Adriamycin^©, mitomycin C, streptozocin)
• FAMTX (5-FU, Adriamycin^©, high-dose methotrexate)
• FAND : fludarabine (25 mg/m² i.v. days 1-3), ara-C (1 g/m² i.v. day 1), Novantrone (mitoxantrone) (10 mg/m² i.v. day 1) and dexamethasone (20 mg i.v. days 1-3)^ref
• FAP (5-FU, Adriamycin^©, Platinol^© (cisplatin))
• FC (fludarabine 20 mg/m²/day IV days 1-5, cyclophosphamide 600 mg/m² IV day 1, G-CSF 5 mg/kg alternibus diebus subcutaneously starting day 8 continuing 10-14 days until ANC >= 10,000/mm³, trimethoprim/sulfamethoxazole PO twice daily every Monday, Wednesday, Friday, allopurinol 300 mg daily days 1-7, cycle 1 only. Repeat cycle every 28 days. Neutropenia grade 3 (20-25%) or 4 (8-18%), anemia grade 3-4 (7%), thrombocytopenia grade 3 (1.6%) or 3/4 (2%), pulmonary grade 3 (3.3%) or 3/4 (18%), grade 3-4 infections (11%), viral reactivation in 7% of patients. Emetogenic potential day 1 level 3, days 2-5 level 1^{ref1, ref2})
• FCAP (5-FU, cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• FCE (5-FU, epirubicin, cyclophosphamide)
• F-CL (5-FU, leucovorin / folinic acid calcium)
• FCM / FLU/CY/MUTI (fludarabine 25 mg/m²/day IV days 1-3, cyclophosphamide 300 mg/m² IV days 1-3, mitoxantrone 10 mg/m² IV day 1). Repeat cycle every 28 days. Leukopenia grade -34 (42%), febrile neutropenia grade 1/2 (16%), anemia grade 1-2 (25%), thrombocytopenia grade 1-2 (27%) (Spriano et al. Ann.Oncol. 13-sippl2 (2002); abstract 502)
• FCP (5-FU, cyclophosphamide, prednisone)
• FEC (5-FU, epirubicin, cyclophosphamide)
• FED (5-FU, etoposide, DDP)
• FIMe (5-FU, ICRF-159, MeCCNU)
• FL (flutamide, leuprolide acetate or flutamide, Lupron depot)
• FLAC (5-FU, leucovorin / folinic acid calcium, Adriamycin^©, cyclophosphamide)
• FLAI : fludarabine + araC + idarubicin
• FLAIG : fludarabine 30 mg/m² (25 mg/m² in patients aged > 70 yrs) + araC 1 g/m² + idarubicin 10 mg/m² in 24 hours continuous perfusion on days 1-3-5 + G-CSF from day 7 to granulocyte recovery
• FLAG-IDA : fludarabine 25 mg/m²/d (d1-5), araC 2 g/m²/d (d1-5), idarubicin 12 mg/m²/d (d1-3), G-CSF s.c. from day 6 until absolute neutrophil count (ANC) >500/ml^ref
• FLAG : fludarabine, cytarabine and G-CSF
• FLAM : sequential fludarabine, cytarabine, and mitoxantrone
• FLANG (fludarabine + cytarabine + Novantrone^© + G-CSF)
• FLAP (5-FU, leucovorin / folinic acid calcium, Adriamycin^©, Platinol^© (cisplatin))
• FLAT (fludarabine, cytarabine and topotecan)
• FLe (5-FU, levamisole)
• FLIDA (fludarabine, idarubicin and prednisone)
• FLU-CTX-IDEC : fludarabine 25 mg/m² days 1-3 IV + cyclophosphamide 300 mg/m² IV days 1-3 + rituximab 375 mg/m² IV day 3. Repeat cycle every 21 days for 6 cycles
• FLU-ID (fludarabine 25 mg/m² days 1-3 IV and idarubicin 12 mg/m² day 1 IV). Repeat cycle every 28 days. Neutropenia grade 3/4 (3.7%), nausea (72.5%) => G-CSF 5 mg/kg sc starting day 8 continuing 10-14 days until ANC >= 10,000/mm³. Emetogenic potential day 1 level 3, days 2, 3 level 1^ref)
• FLU-VEL-MYO :  fludarabine 25 mg/m² days 1, 4, 8, Velcade^© (bortezomib) 1 mg/m2 on days 1, 4, 8, 11, liposomal doxorubicin (Myocet^©) 50 mg/m² IV on day 4 (+ rituximab 375 mg/m² IV on days 1, 4, 8 and 11 of 2nd cycle). Repeat cycle every 21 days for 3 cycles.
• FM (fludarabine25 mg/m²/day IV over 30 minutes days 1-3 (1-5), mitoxantrone 10 mg/m² IV day 1. Repeat cycle every 28 days. Neutropenia grade 3 (22%) or 4 (18%), anemia grade 1 (18%) or 2 (4%), grade 3-4 neutropenic fever (11%), alopecia (11%) => G-CSF 5 mg/kg sc used in 18% of patients starting day 8 continuing 10-14 days until ANC >= 10,000/mm³. Emetogenic potential day 1 level 3, days 2, 3 level 1^ref)
• F-MACHOP (cyclophosphamide 750 mg/m² IV day 3, Adriamycin^©(doxorubicin) 60 mg/m² IV day 3, vincristine 1 mg/m² IV days 1-2, cytarabine 1 g/m² IV day 3, 5-FU 600 mg/m² IV day 3, methotrexate 495 mg/m² IV day 4 with folic acid rescue. Repeat cycle every 4 weeks. Grade 3/4 neutropenia (59%), grade 3 anemia (21%), grade 1/2 neuropathy (53%), grade 3/4 mucositis (90%), alopecia (100%), osteoarthromyalgia (58%), hepatic grade 1/2 (43%) or 3/4 (3%)^ref
• FMD : see FND
• FM-R (fludarabine 25 mg/m²/day IV over 30 minutes days 1-3, mitoxantrone 10 mg/m² IV day 1, rituximab 375 mg/m² IV day 1)
• FMS (5-FU, mitomycin C, streptozocin)
• FND (fludarabine 25 mg/m²/day IV days 1-3, mitoxantrone 10 mg/m² IV day 1, and dexamethasone 20 mg/day PO days 1-5; G-CSF 5 mg/kg sc starting day 8 continuing 10-14 days until ANC >= 10,000/mm³. Repeat cycle every 21-28 days for 6 cycles. Protocol amended to include PCP prophylaxis. Grade 4 neutropenia (20%), grade 3-4 febrile neutropenia (3.8%), thrombocytopenia (< 50,000 : 8%; 50,000-100,000 : 31%) => hematologic recovery delayed to > 35 days in 9% of courses, 6 patients required dose reductions secondary to myelosuppression, 9 patients had early discontinuationn of therapy due to myelosuppression. Emetogenic potential day 1 level 3, days 2, 3 level 1^ref)
• FND-R : FND + rituximab 375 mg/m² IV day 1
• FMV (5-FU, MeCCNU, vincristine)
• FNM (5-FU, Novantrone^©, methotrexate)
• FOAM (5-FU, Oncovin^© (vincristine), Adriamycin^©, mitomycin C)
• FOLFIRI : a 30- to 90-minute infusion of irinotecan at a dose of 180 mg/m² of body-surface area; an infusion, for 120 minutes, of racemic leucovorin / folinic acid calcium or L-leucovorin at a dose of 400 or 200 mg/m², respectively; 5-FU in a bolus of 400 mg/m² and then continuous infusion for 46 hours of 2400 mg/m²
• FOM (5-FU, Oncovin^© (vincristine), mitomycin C)
• FOMi (5-FU, Oncovin^© (vincristine), mitomycin C)
• FR : during the first week of the study, patients received 2 infusions of rituximab 375 mg/m² administered 4 days apart. 72 hours after the second infusion of rituximab, patients received the first of 6 cycles of fludarabine chemotherapy (25 mg/m²/d for 5 days on a 28-day cycle). Single infusions of rituximab were administered 72 hours before the second, fourth, and sixth cycles of fludarabine, and two infusions of rituximab were given 4 weeks after the last cycle of fludarabine. Treatment duration was 26 weeks)^{ref1, ref2}
• FRACON (framycetin, colistin, nystatin)
• FUM (5-FU, methotrexate)
• FURAM (ftorafur, Adriamycin^©, mitomycin C)
• FUVAC (5-FU, vinblastine, Adriamycin^©, cyclophosphamide)
• GDP : gemcitabine 1000 mg/m² IV on days 1 and 8, dexamethasone 40 mg p.o. days 1-4 + cisplatin 75 mg/m² on day 1. Repeat cycle every 21 days. All patients had successful stem cell mobilization and underwent transplantation with a median 10.6 x 10⁶ CD34⁺ cells/kg. Hematological toxicity from GDP was mild (grade 3 neutropenia 8.6%, grade 3 thrombocytopenia 13%)^{ref1, ref2, ref3, ref4}
• GDP-R : GDP + rituximab 375 mg/m² IV
• GEMOX-R : rituximab 375 mg/m² IV on day 1, gemcitabine 1000 mg/m² on day 1 and oxaliplatin 100 mg/m²on day 1. Treatment is repeated in 2 weeks intervals if feasible or every 3 weks for a planed 6-8 courses with staging after the third course.
• GEM-P (gemcitabine 1000 mg/m² IV days 1, 8, 15, cisplatin 100 mg/m² IV over 4 hours day 15 (administer 4 hours following gemcitabine), methylprednisolone 1000 mg/day PO/IV days 1-5. Repeat cycle every 28 days. Prophylaxis against Pneumocystic carinii pneumonia administered to all patients. Neutropenia grade 3 (48%) or 4 (24%), leukopenia grade 3 (38%) or 4 (24%), anemia grade 0-2 (91%) or 3 (10%), thrombocytopenia (48%) => 5 patients required G-CSF support, 38% of patients required blood product support. Dose reductions and dose delays occurred frequently. Emetogenic potential days 1, 8 level 2, day 15 level 5^ref.
• R-GIFOX : rituximab 375 mg/m² IV on day 1, gemcitabine (1000 mg/m² on day 2), oxaliplatin (130 mg/m² on day 3) and ifosfamide (5 g/m² on day 3) as a 24-h single infusion in patients aged < or =65 years, or fractionated over 3 days (days 3-5) in patients aged >65 years. Treatment was given every 2 weeks for 4 cycles with G-CSF support (5 mg/kg/day or 10 microg/kg/day at the end of the third course for HSC mobilization)
• GM-IVA (GM-CSF, ara-C, VP-16 and idarubicin)
• HAD (hexamethylmelamine, Adriamycin^©, DDP)
• HAM (hexamethylmelamine, Adriamycin^©, melphalan or hexamethylmelamine, Adriamycin^©, methotrexate)
• HAMP (hexamethylmelamine, Adriamycin^©, methotrexate, Platinol^© (cisplatin))
• HCAO (hexamethylmelamine, cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• H-CAP (hexamethylmelamine, cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• HD-CTX : cyclophosphamide 4 g/m² followed by HSC collection
• HDMTX-CF (high-dose methotrexate, citrovorum factor)
• HDMTX/LV (high-dose methotrexate, leucovorin / folinic acid calcium)
• HDPEB (high-dose PEB or Platinol^© (cisplatin), etoposide, bleomycin)
• high-dose sequential (HDS) chemotherapy : HD-CTX with PBPC harvesting, followed by ... :
• Cologne HDS : methotrexate 8 g/m² (day 1) + Oncovin^© (vincristine) 1.4 mg/m² (day 51) + etoposide 500 mg/m² (day 58-62) followed by a final myeloblative course (BEAM)^{ref1, ref2}
• Torino HDS : methotrexate, etoposide, then HDT (usually hd mitoxantrone plus L-phenylalanine mustard) ^ref
• HD-VAC (high-dose methotrexate plus vinblastine, Adriamycin^©, cisplatin)
• Hexa-CAF (Hexalen^© (hexamethylmelamine), cyclophosphamide, Adrucil^© (5-FU), Folex^© (methotrexate))
• HiC-COM (ara-C, citrovorum factor, allopurinol, Elliot B solution, cyclophosphamide, Oncovin^© (vincristine), methotrexate)
• high-risk ATAC (L-asparaginase, ara-C, VP-16, anti-J2 26 mAb, anti-CALLA hybridoma antibody)
• HOAP-BLEO (hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), ara-C, prednisone, bleomycin)
• HOP (hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), prednisone)
• ICE (see also mini-ICE):
• etoposide 100 mg/m²/day IV days 1-3, carboplatin dose targeted by Calvert equation to AUC of 5 (maximum dose 800 mg) IV day 2, ifosfamide 5 g/m²  IV continuous infusion over 24 hours day 2 (with 100% replacement with mesna : mesna was mixed in the bag with ifosfamide. The published regimen does not include another 24 hours of mesna, but based on the excretion of ifosfamide, another 12-24 hours of mesna administered by IV continouous infusion would be recommended following completion of ifosfamide. Grade 3-4 neutropenia (21%), anemia grade 1 (24%), 2 (32%), 3 (23%), 4 (4%), thrombocytopenia (29%), increased AlkP (2x) (11%), increased ALT (2x) (10%), neurotoxicity (3%) => 13% of grade 4 neutropenia patients hospitalized. Emetogenic potential day 1 level 2, day 2 level 5, day 3 level 2^ref
• idarubicin + cytarabine + etoposide
• ifosfamide 1.5 g/m², carboplatin 100 mg/m² and etoposide 150 mg/m², days 1-4, q 28 days, G-CSF 5 mg/kg starting from day 6^ref
• ibritumomab tiuxetan + rituximab : rituximab 250 mg/m² IV day 1 followed within 4 hours by In-111 ibritumomab tiuxetan (5 mCi In-111; 1.6 mg ibritumomab tiuxetan), rituximab 250 mg/m² IV day 8 folowed within 4 hours by Y⁹⁰ ibritumomab tiuxetan 0.4 mCi/kg (not to exceed 32 mCi). Appropriate premedications. Neutropenia (grade 3 : 25%, grade 4 : 32%), anemia grade 3 (1%) or 4 (1%), thrombocytopenia (60%), asthenia (4%), pain (1%) => 5 patients hospitalized with infection or febrile neutropenia. Emetogenic potential : day 1 level 1, day 8 level 1)^ref
• IEV (ifosfamide (+ mesna) 2.5 g/m² iv on days 1-3, epirubicin 100 mg/m² on day 1, and VePesid^© (etoposide) 150 mg/m² on days 1-3). Repeat cycles every 3 weeks for a total  of 3 cycles. Add G-CSF for cytoreduction and stem cell mobilization. Grade 3-4 neutropenia (90%), grade 3 infections (15%), anemia (18%), thrombocytopenia (12%), nausea/vomiting (4%), alopecia (100%), and neurologic toxicity (3%)^{ref1, ref2, ref3}. IEV + autologous PBSCT is a feasible and effective salvage treatment for lymphoid malignancies^ref
• IFL : irinotecan, 5-FU, and leucovorin calcium
• IGEV (ifosfamide (+ mesna) 2 g/m² iv on days 1-4, gemcitabine 800 mg/m² iv days 1 and 4, day 1, vinorelbine 20 mg/m² iv day 1). Repeat cycle every 3 weeks for 2-4 cycles. Neutropenia grade 3 (15%) or 4 (50%), infections grade 1-2 (6%) or 3 (8%), grade 3 anemia (9%), thrombocytopenia grade 1/2 (17%) or 4 (2%), stomatitis (5%), hemorrhagic cystitis (20%)^{ref1, ref2}
• IMF (Ifex^© (ifosfamide), mesna, Folex^© (methotrexate), 5-FU)
• IMVP-16 (ifosfamide, methotrexate, VP-16)
• IVAC : ifosfamide 1500 mg/m²/day IV over 1 hour days 1-5, etoposide 60 mg/m²/day IV over 1 hours days 1-5, mesna 360 mg/m² IV over 1 hours (1 dose mixed with ifosfamide), followed by mesna 360 mg/m² IV over 15 minutes every 3 hours days 1-5) and high-dose cytarabine 2000 mg/m² IV over 3 hours every 12 hours days 1, 2 (a total of 4 doses); methotrexate intratechal 12 mg x 1 day 5; GM-CSF 7.5 mcg/kg/day subcutaneously day 7 onward. Neutropenia grade 4 (100%), leukopenia grade 4 (100%), thrombocytopenia (97% < 18 years; 100% >= 18 years), grade 3 stomatitis (6% < 18 years, 3% >= 18 years), grade 4 stomatitis (3% < 18 years), grade 3 hepatotoxicity (5.9% < 18 years) => documented infections in 55% of cycles, average duration of neutropenia 11 days. Emetogenic potential days 1-2 level 5, days 3-5 level 4. Regimen consistes of alternating cycles of CODOX-M and IVAC for a total of 4 cycles. Patients with CNS disease at presentation received additional intratechal therapy during the first cycle of IVAC as follows: intratechal cytarabine on days 7, 9^{ref1, ref2}
• KGC (Keflin^© (cephalotin), gentamicin, carbenicillin)
• LAM (L-asparaginase, methotrexate)
• LAPOCA (L-asparaginase, prednisone, Oncovin^© (vincristine), cytarabine, Adriamycin^©)
• Larson regimen^ref :
• course I : induction (4 weeks) : cyclophosphamide 1200 mg/m² IV day 1, daunorubicin 45 mg/m²/day IV days 1-3, vincristine 2 mg IV days 1, 8, 15, 22, prednisone 60 mg/m²/day PO days 1-21, L-asparaginase (E.coli) 6000 units/m² subcutaneously/IM days 5, 8, 11, 15, 18, 22), G-CSF 5 mcg/kg/day subcutaneously starting day 4 and continuing until ANC >= 1000 on 2 consecutive days > 24 hours apart. For patients 60 years and older, reduce the following doses : cyclophosphamide 800 mg/m² IV day 1, daunorubicin 30 mg/m2 IV days 1-3, prednisone 60 mg/m²/day PO days 1-7
• leukopenia grade 3-5 (98% with G-CSF, 97% without G-CSF), anemia grade 3-5 (93% with G-CSF, 86% without G-CSF)
• other grade 3-4 toxicities : infection grade 3-5 (78% with G-CSF, 87% without G-CSF), thrombocytopenia grade 3-5 (97% with G-CSF, 95% without G-CSF), hyperbilirubinemia grade 3-5 (48%), transaminases > 5x ULN (35%), nausea grade 3-5 (26%), malaise/fatigue grade 3-5 (21%) => hematologic recovery (G-CSF vs.placebo) : ANC > 1000 16 vs. 22 days, duration of neutropenia 13 vs. 20 days, platelets > 50,000 16 vs. 19 days, fever > 38.5°C 3 s. 3 days, hospitalization 22 vs. 28 days
• emetogenic potential : day 1 level 5, days 2-3 level 3, days 5, 8, 11, 15, 18, 22 level 2
• course IIA : early intensification (4 weeks, repeat once for course IIB) : intratechal methotrexate mg day 1, cyclophosphamide 1000 mg/m² IV day 1, 6-mercaptopurine 60 mg/m²/day PO days 1-14, cytarabine 75 mg/m²/day subcutaneously days 1-4 and days 8-11, vincristine 2 mg IV days 15, 22, L-asparaginase (E.coli) 6000 units/m² subcutaneously/IM days 15, 18, 22, 25, G-CSF 5 mg/kg/day subcutaneously starting day 2 and continuing for at least 14 days and until ANC >= 5000
• emetogenic potential : day 1 level 5, days 2-4 and 11-14 level 2, days 5-11 level 1, and days 15, 18, 22, 25 level 2
• hematologic recovery (G-CSF vs.placebo) : ANC > 1000 20 vs. 29 days, duration of neutropenia 5 vs. 13 days, fever > 38.5°C 0 s. 0 days, hospitalization 7 vs. 3 days
• course III : CNS prophylaxis and interim maintenance (12 weeks) : cranial irradiation (see article), intratechal methotrexate 15 mg days 1, 8, 15, 22, 29, 6-mercaptopurine 60 mg/m²/day PO days 1-70, methotrexate 20 mg/m² PO days 36, 43, 50, 50, 57, 64. Emetogenic potential : days 1-70 level 1
• course IV : late intensification (8 weeks) : doxorubicin 30 mg/m² IV days 1, 8, 15, vincristine 2 mg IV days 1, 8, 15, dexamethasone 10 mg/m²/day PO days 1-14, cyclophosphamide1000 mg/m² IV day 29, 6-thioguanine 60 mg/m²/day PO days 29-42, cytarabine 75 mg/m²/day subcutaneously days 29-32 and days 36-39. Emetogenic potential : days 1, 8, 15 level 3, day 29 level 5, days 30-32 and 36-39 level 2, days 34-35 and 40-42 level 1
• course V (prolonged maintenance until 24 months from diagnosis) : vincristine 2 mg IV day 1 of every 4-week period, prednisone 60 mg/m²/day PO days 1-5 of every 4-week period, 6-mercaptopurine 60 mg/m²/day PO days 1-28, methotrexate 20 mg/m² PO days 1, 8, 15, 22. Emetogenic potential : days 1-28 level 1
• Linker regimen^ref : treatment consists of a total of 7 courses, given in order of 1A, 1B, 1C, 2A, 2B, 2C, and 3C, followed by maintenance chemotherapy. See original article for CNS treatment and maintenance therapy. All patients received PCP prophylaxis from the start of treatment until the end of maintenance therapy
• induction 1A : daunorubicin 60 mg/m² IV days 1-3 (and day 15 if day 14 bone marrow has residual leukemia), vincristine 1.4 mg/m² IV days 1, 8, 15, 22 (cap dose at 2 mg for patients > 40 years), prednisone 60 mg/m² PO days 1-28, L-asparaginase (E.coli) 6000 units/m² subcutaneously days 17-28. Time to ANC > 500 (median) : 18 days; time to ANC > 1000 (median) : 23 days; days ANC < 500 (median) : 14. Emetogenic potential : days 1-3 level 3, days 8, 15, 22 level 1, days 17-28 level 2. 1 treatment-related death
• consolidation (1B, 2B) : cytarabine 2000 mg/m²/day IV over 2 hours days 1-4, etoposide 500 mg/m²/day IV over 3 hours days 1-4, G-CSF 5 mg/kg/day starting day 14 until ANC > 1500 for 2 days. Time to ANC > 500 (median) : 19 days (1B), 20 days (2B); time to ANC > 1000 (median) : 20 days; days ANC < 500 (median) : 12. Emetogenic potential : days 1-4 level 5
• consolidation 2A : daunorubicin 60 mg/m²/day IV days 1-3, vincristine 1.4 mg/m² IV days 1, 8, 15 (capped at 2 mg if > 40 years), prednisone 60 mg/m²/day PO days 1-21, L-asparaginase (E.coli) 12,000 units/m² subcutaneously for 6 doses over 2 weeks. Time to ANC > 500 (median) : 16 days; time to ANC > 1000 (median) : 17 days; days ANC < 500 (median) : 5. Emetogenic potential : days 1-3 level 3, days 8, 15 level 1, days of asparaginase level 2
• consolidation 1C, 2C, 3C : methotrexate 220 mg/m² IV bolus followed by 60 mg/m²/hour for 36 hours days 1, 2, 15, 16, leucovorin 50 mg/m² IV every 6 hours for 3 doses, then oral leucovorin until methotrexate level < 0.05 mM/L, 6-mercaptopurine 75 mg/day PO days 1-28. Emetogenic potential : days 1, 2, 15, 16 level 4, days 3-14, 17-28 level 1
• LMF (Leukeran^© (chlorambucil), methotrexate, 5-FU)
• LOMAC (leucovorin / folinic acid calcium, Oncovin^© (vincristine), methotrexate, Adriamycin^©, cyclophosphamide)
• L-VAM (Lupron, Velban^© (vinblastine), Adriamycin^©, mitomycin C)
• LVVP (Leukeran^© (chlorambucil), vinblastine, vincristine, prednisone)
• M2 (vincristine, carmustine, cyclophosphamide, melphalan, prednisone)
• MABOP (mechlorethamine, Adriamycin^©, bleomycin, Oncovin^© (vincristine), prednisone)
• MAC (methotrexate, actinomycin-D, cyclophosphamide or methotrexate, Adriamycin^©, cyclophosphamide or mitomycin C, Adriamycin^©, cyclophosphamide)
• MACC (methotrexate, Adriamycin^©, cyclophosphamide, CCNU)
• MACHO (methotrexate, L-asparaginase, cyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine))
• MAD (MeCCNU, Adriamycin^©)
• MADDOC (mechlorethamine, Adriamycin^©, dacarbazine, DDP, Oncovin^© (vincristine), cyclophosphamide)
• MAID (mesna, Adriamycin^©, IL-3, dacarbazine or mesna, Adriamycin^©, ifosfamide, dacarbazine)
• MAP (melphalan, Adriamycin^©, prednisone or mitomycin C, Adriamycin^©, Platinol^© (cisplatin))
• MAZE (m-AMSA, azacitidine, etoposide)
• M-BACOS (methotrexate, bleomycin, Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), Solu-Medrol (methylprednisolone))
• M-BAM (cyclophosphamide, total body irradiation, monoclonal antibodies)
• MBC (methotrexate, bleomycin, cisplatin)
• MBD (methotrexate, bleomycin, cisplatin)
• MC (mitoxantrone, cytarabine)
• MCBP (melphalan, cyclophosphamide, BCNU, prednisone)
• MCP (melphalan, cyclophosphamide, prednisone)
• MCV (methotrexate, cisplatin, vinblastine)
• MDLO (metoclopramide, dexamethasone, lorazepam, ondansetron)
• MECY (methotrexate, cyclophosphamide)
• MeFA (MeCCNU, 5-FU, Adriamycin^©)
• MF (methotrexate, 5-FU or mitomycin C, 5-FU)
• MFP (melphalan, 5-FU, Provera^© (medroxyprogesterone))
• MICE (mesna rescue, ifosfamide, carboplatin, etoposide)
• MIFA (mitomycin C, 5-FU, Adriamycin^©)
• MIFAP : fludarabine (15 mg/m², q. 12 h, day 1-4), cytarabine (50 mg/m² by continuous infusion (CI) over 22 h, day 1-4), cisplatin (25 or 30 mg/m² by CI over 24 h, day 1-4), and mitoxantrone (4 mg/m², day 2-5)^ref
• MINE (mesna, ifosfamide, Novantrone^©, etoposide)
• mini-BEAM : BCNU 60 mg/m²/day, etoposide 300 mg/m²/day, araC 800 mg/m²/day and melphalan 30 mg/m²/day for one day. Repeat cycle every 4 weeks for 2-3 cycles^ref
• mini-COAP (cyclophosphamide, Oncovin^© (vincristine), ara-C, prednisone)
• mini-ICE : idarubicin 8 mg/m²/day i.v. bolus injection for 3 days, cytarabine 800 mg/m²/day as a 2 h i.v. infusion for 3 days and etoposide 150 mg/m²/day as a 2 h i.v. infusion for 3 days, plus glycosylated G-CSF 5 mg/kg/day s.c. from day 8^ref
• 5-d Mini-ICE (oral idarubicin and etoposide; subcutaneous cytarabine)^{ref1, ref2, ref3}
• MM (6-mercaptopurine, methotrexate)
• MMOPP (methotrexate, mechlorethamine, Oncovin^© (vincristine), procarbazine, prednisone)
• MMPR (methylmercaptopurine)
• MMPT (methylprednisolone pulse therapy)
• MNA (N-monomethyl-L-arginine)
• MOAD (methotrexate, Oncovin^© (vincristine), L-asparaginase, dexamethasone)
• MOAP (pegasparaginase, Oncovin^© (vincristine), methotrexate, prednisone)
• MOB (Mustargen^© (mechlorethamine), Oncovin^© (vincristine), bleomycin)
• MOB-III (mitomycin C, Oncovin^© (vincristine), bleomycin, cisplatin)
• MOCA (methotrexate, Oncovin^© (vincristine), cyclophosphamide, Adriamycin^©)
• MOF (MeCCNU, Oncovin^© (vincristine), 5-FU or methotrexate, Oncovin^© (vincristine), 5-FU)
• MOF-STREP (MeCCNU, Oncovin^© (vincristine), 5-FU)
• MOMP (mechlorethamine, Oncovin^© (vincristine), methotrexate, prednisone)
• MOP (mechlorethamine, Oncovin^© (vincristine), prednisone or (mechlorethamine, Oncovin^© (vincristine), procarbazine or melphalan, Oncovin^© (vincristine), methylprednisolone)
• MOP-BAP (mechlorethamine, Oncovin^© (vincristine), procarbazine, bleomycin, Adriamycin^©, prednisone)
• MOPP : mechlorethamine 6 mg/m² IV days 1, 8, Oncovin^© (vincristine) 1.4 mg/m² IV days 1, 8 (maximum 2 mg), procarbazine 100 mg/m²/day PO days 1-14, prednisone 40 mg/m²/day PO days 1-14. Repeat cycle every 28 days. Neutropenia grade 3 (47%), 4 (21%) or 5 (1%), anemia grade 3 (31%) or 4 (12%), grade 4 infection (12%), grade 3-4 thrombocytopenia (51%), grade 3 nausea/vomiting (28%), grade 3 peripheral neuropathy (8%), grade 3 alopecia (5%), grade 3-4 pulmonary toxicity (4%) => gradual reduction of dose intensity to 24% by cycle 6. Emetogenic potential : days 1, 8 level 5, days 2-7 level 4, days 9-14 level 4^{ref1, ref2}
• MOPP-ABV (mechlorethamine, Oncovin^© (vincristine), procarbazine, prednisone, Adriamycin^©, bleomycin, vinblastine) (Conners JM, Klimo P, Adams G, Burns B, Cooper I, Meyer R, et al. MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin’s disease. Proc Am Soc Clin Oncol 1992;11:317)
• MOPP-ABVD (mechlorethamine 6 mg/m² i.v. at day 1, Oncovin^© (vincristine) 1.4 mg/m² (max 2 mg) i.v. at day 1, procarbazine 100 mg/m² p.o. since day 1 to day 7, prednisone  40 mg/m² p.o. since day 1 to day 7 + Adriamycin^© 35 mg/m² iv. day 8, bleomycin 10 U/m² iv day 8, vinblastine 6 mg/m² iv day 8). Grade 4 leukopenia (28.4%), grade 3 nausea/vomiting (11.9%), grade 3 hepatic toxicity (4.5%)^{ref1, ref2, ref3}
• C-MOPP-ABVd (cyclophosphamide 500 mg/m² drip i.v. at days 1, 8, Oncovin^© (vincristine) 1.4 mg/m² (max 2 mg) i.v. at day 1, 8, procarbazine 100 mg/m² (max 150 mg) p.o. since day 1 to day 14, prednisone  40 mg/m² p.o. days 1-3 and 8-10 + Adriamycin^© 25 mg/m² i.v. at day 1 and 15, bleomycin 9 mg/m² (max 15 mg) i.v. at day 1 and 15, vinblastine 6 mg/m² (max 10 mg) i.v. at day 1 and 15, dacarbazine 250 mg/m² drip i.v. at day 1 and 15)^ref
• MOPP-LO BLEO (mechlorethamine, Oncovin^© (vincristine), procarbazine, prednisone, bleomycin)
• MOPPHDB (mechlorethamine, Oncovin^© (vincristine), procarbazine, prednisone, high-dose bleomycin)
• MOPPHDB (mechlorethamine, Oncovin^© (vincristine), procarbazine, prednisone, low-dose bleomycin)
• MOPr (mechlorethamine, Oncovin^© (vincristine), procarbazine)
• MP (melphalan 8 mg/m²/day PO days 1-4, prednisone 60 mg/m²/day PO days 1-4. Repeat cycle every 28 days. Neutropenia grade 3 (29%) or 4 (8%), infections (14%), thrombocytopenia (23%), nausea/vomiting (10%), alopecia (7%), peripheral neuropathy (2%). Emetogenic potential days 1-4 level 1^ref)
• MPFL (methotrexate, Platinol^© (cisplatin), 5-FU, leucovorin / folinic acid calcium)
• MPL + PRED (melphalan, prednisone)
• MPT :
• MPV
• methotrexate, procarbazine, and vincristine
• see VMP
• MTV (methotrexate, thiotepa, and vincristine)
• MTX + MP (methotrexate, 6-mercaptopurine)
• MTX + MP + CTX (methotrexate, 6-mercaptopurine, Cytoxan^© (cyclophosphamide))
• MV (mitoxantrone, VP-16)
• M-VAC : methotrexate, vinblastine, doxorubicin, and cisplatin
• MVF (mitoxantrone, vincristine, 5-FU)
• MVP (mitomycin C, vinblastine, Platinol^© (cisplatin))
• MVPP (mechlorethamine, vinblastine, procarbazine, prednisone)
• MVT (mitoxantrone, VP-16, thiotepa)
• MVVPP (mechlorethamine, vincristine, vinblastine, procarbazine, prednisone)
• NAC (nitrogen mustard, Adriamycin^©, CCNU)
• NOPP : mitoxantrone 10 mg/m² i.v. day 1, Oncovin^© (vincristine) 1.4 mg/m² i.v. day 1, procarbazine 100 mg/m² p.o. day 1-14,prednisone 100 mg/m² p.o. day 1-5
• OAP (Oncovin^© (vincristine), ara-C, prednisone)
• OAP-BLEO (Oncovin^© (vincristine), ara-C, prednisone, bleomycin)
• O-DAP (Oncovin^© (vincristine), dianhydrogalactitol, Adriamycin^©, Platinol^©(cisplatin))
• OMAD (Oncovin^© (vincristine), methotrexate, Adriamycin^©, dactinomycin)
• ONCEP-PSC : Oncovin^© (vincristine), Novantrone^©(mitoxantrone), cyclophosphamide, etoposide, prednisone, PSC 833
• OPAL (Oncovin^© (vincristine), prednisone, L-asparaginase)
• OPEN (Oncovin^© (vincristine), prednisone, etoposide, Novantrone^©)
• OPP (Oncovin^© (vincristine), procarbazine, prednisone)
• OPPA (Oncovin^© (vincristine), procarbazine, prednisone, Adriamycin^©)
• PAB-Esc-C (Platinol^© (cisplatin), Adriamycin^©, bleomycin, escalating doses of cyclophosphamide)
• PABLOE (prednisone, doxorubicin, bleomycin, Oncovin^© (vincristine) and etoposide)
• PAC (Platinol^© (cisplatin), Adriamycin^©, cyclophosphamide)
• PACE (4 days of IV continuous-infusion Platinol^© (cisplatin) 10 mg/m²/day, Adriamycin^© (doxorubicin) 10 mg/m²/day, cyclophosphamide 400 mg/m²/day, and etoposide 40 mg/m²/day) for small-cell lung cancer^{ref1, ref2}, advanced thymoma or thymic cancer (cisplatin (80 mg/m², on day 1), doxorubicin (45 mg/m², on day 1), cyclophosphamide (800 mg/m², on day 1) and etoposide (80 mg/m², on day 1-3) with G-CSF (90 mg/m², on day 5-18))^ref, and follicular lymphoma
• PAD : PS-341 / bortezomib 1.3 mg/m² days 1, 4, 8, 11, Adriamycin^© (doxorubicin) 9 mg/m² IV days 1-4, dexamethasone 40 mg PO days 1-4, 8-11, and 15-18 at cycle 1 and days 1-4 at cycles 2-4. 4 3-week cycles.
• PATCO (prednisone, ara-C, thioguanine, cyclophosphamide, Oncovin^© (vincristine))
• PAVe (procarbazine, Alkeran^© (melphalan), Velban^© (vinblastine))
• PBV (Platinol^© (cisplatin), bleomycin, vinblastine)
• PCE (Platinol^© (cisplatin), cyclophosphamide, Eldisine^© (vindesine))
• PCV (procarbazine, CCNU, vincristine)
• PCVT (procarbazine, CCNU, vincristine, and thioguanine)
• PEB (Platinol^© (cisplatin), etoposide, bleomycin)
• PEC (Platinol^© (cisplatin), etoposide, cyclophosphamide)
• PELF (epirubicin + CDDP + leucovorin / folinic acid calcium+ 5-FU)
• PEP (Procytox^© (cyclophosphamide), epipodophyllotoxin-derivative, prednisolone)
• PF + E (Platinol^© (cisplatin), 5-FU plus etoposide, methotrexate, leucovorin / folinic acid calcium)
• PFL (Platinum, 5-FU, leucovorin / folinic acid calcium)
• PFM (Platinol^© (cisplatin), 5-FU, methotrexate)
• PFT (L-phenyl-alanine mustard, 5-FU, tamoxifen)
• PHRT (procarbazine, hydroxyurea (HU), radiotherapy)
• PIA (Platinol^© (cisplatin), ifosfamide, Adriamycin^©)
• PMB (Platinol^© (cisplatin), methotrexate, bleomycin)
• PMF (L-phenyl-alanine mustard, methotrexate, 5-FU)
• PMFAC (prednisone, methotrexate, 5-FU, Adriamycin^©, cyclophosphamide)
• P-MVAC (Platinol^© (cisplatin), methotrexate, vinblastine, Adriamycin^©, carboplatin)
• POC (procarbazine, Oncovin^© (vincristine), CCNU)
• POCA (prednisone, Oncovin^© (vincristine), cytarabine, Adriamycin^©)
• POCC (procarbazine, Oncovin^© (vincristine), cyclophosphamide, CCNU)
• POMP (prednisone, Oncovin^© (vincristine), methotrexate, Purinethol^© (6-mercaptopurine))
• PRH-E (Platinol^© (cisplatin), etanidazole)
• PRIME (procarbazine, ifosfamide, methotrexate)
• ProMACE (prednisone, methotrexate, Adriamycin^©, cyclophosphamide, etoposide)
• ProMACE-MOPP (procarbazine, methotrexate, Adriamycin^©, cyclophosphamide, etoposide, mechlorethamine, Oncovin^© (vincristine), procarbazine, prednisone)
• pulse VAC (vincristine, actinomycin-D, cyclophosphamide)
• PVA (prednisone, vincristine, L-asparaginase)
• P-VABEC (see also VACOP-B): VePesid^© (etoposide) 100 mg i.v. on day 1, Adriamycin^© (doxorubicin) 30 mg/m²/day i.v. day 1, cyclophosphamide 330 mg/m² i.v. on day 1, Oncovin^© (vincristine) 8 mg/m² on day 1, prednisone 50 mg abs. p.o. on days 1–14, and bleomycin 8 mg/m² on day 1^{ref1, ref2, ref3, ref4}
• R-P-VABEC : P-VABEC + rituximab 375 mg/m² IV day 8
• PVB : Platinol^© (cisplatin), vinblastine and bleomycin
• PVDA (prednisone, vincristine, daunorubicin, L-asparaginase)
• PVI (Platinol^© (cisplatin), vinblastine and ifosfamide)
• PVP (Platinol^© (cisplatin), VP-16)
• RICE + A109 (rituximab 375 mg/m² IV day 1, ifosfamide 5000 mg/m² IV continuous infusion over 24 hours day 3, mesna 5000 mg/m² IV continuous infusion over 24 hours day 4, carboplatin dose targeted by Calvert equation to AUC of 5 (maximum dose 800 mg) IV day 4, etoposide 100 mg/m²/day IV days 3-5, G-CSF 5 mg/kg/day subcutaneously days 7-14 after cycles 1 and 2. Repeat cycle every 14 days. Appropriate premedications. Mesna was mixed in the bag with ifosfamide. The published regimen does not include another 24 hours of mesna, but based on the excretion of ifosfamide, another 12-24 hours of mesna administered by IV continuous infusion would be recommended following completion of ifosfamide. G-CSF dose increased to 10 mg/kg/day subcutaneously days 7-14 after the third cycle until the end of leukapheresis. Neutropenia cycle 1 (16%) or 2 (14%), neutropenic fever (22%), infection (11%), thrombocytopenia cycle 1 (16%) or 2 (22%), cardiac ischemia (5%), DVT/PE (5%), hemorrhagic cystitis (5%), nausea/vomiting (5%), syncope (3%). Emetogenic potential day 1 level 1, day 3 level 2, day 4 level 5, day 5 level 2^ref)
• RICE / R-ICE outpatient version (rituximab 375 mg/m² IV days 1, 7, 14, ifosfamide 2000 mg/m²/dayIV over 1 hour days 2-4, mesna 1200 mg/m²/day IV days 2-4, mesna 80 mg/m² PO 2 hours and 6 hours after the ifosfamide dose, carboplatin dose targeted by Calvert equation to AUC of 1.67 (maximum dose 350 mg/m²/day) IV days 2-4, etoposide 75 mg/m²/day IV over 2 hours days 2-4. Repeat cycle every 21 days. Appropriate premedications. Neutropenia grade 2 (18%) or 4 (57%), anemia grade 3-4 (18%), fever (4%), thrombocytopenia (49%), elevated creatinine (2), nausea (2%), chemotherapy was administed in an outpatient setting : 8 out of 28 patients required admission to hospital (4 for neutropenic fever). Emetogenic potential day 1 level 1, days 2-4 level 5^ref
• RIDD (recombinant IL-2, dacarbazine, DDP)
• ROAP (Rubidazone^© (zorubicin), Oncovin^© (vincristine), ara-C, prednisone)
• SAM (streptozocin, Adriamycin^©, MeCCNU)
• SCAB (streptozocin, CCNU, Adriamycin^©, bleomycin)
• SIMAL-pilot (ara-C, hydrocortisone, mesna, prednisone, VP-16, leucovorin / folinic acid calcium)
• SIMAL-second induction/maintenance (prednisone, L-asparaginase, daunomycin, VM-26 / teniposide, methotrexate, ara-C, VP-16, leucovorin / folinic acid calcium)
• SIMAL-bone marrow transplant (ara-C, methotrexate, prednisone)
• SMF (streptozocin, mitomycin C, 5-FU)
• Stanford V is only a moderately intensive chemotherapy regimen but includes extensive radiotherapy consolidation in most patients : mechlorethamine 6 mg/m² IV day 1, doxorubicin 25 mg/m² IV days 1, 15, vinblastine 6 mg/m² IV days 1, 15, vincristine 1.4 mg/m² (maximum 2 mg) IV days 8, 22, bleomycin 5 units/m² IV days 8, 22, etoposide 60 mg/m² IV days 15, 16, prednisone 40 mg/m² PO every other day, dose tapered by 10 mg every other day starting at the end of week 10. Repeat cycle every 28 days for a total of 3 cycles. Appropriate premedications. In patients >= 50 years of age, vinblastine dose decreased to 4 mg/m², and vincristine dose decreased to 1 mg/m² during cycle 3. Concomitant trimethoprim/sulfamethoxazole; acyclovir, H₂ antagonists, and stool softeners used. Neutropenia grade 4 (82%), anemia grade 3 (27%) or 4 (4%), grade 3-4 febrile neutropenia (14%), grade 3 constipation (11%), grade 3 fatigue (7%), grade 3 pain (7%), grade 3 neurosensory (6%), grade 3 neuromuscular (4%) => 25% of patients hospitalized, deep vein thrombosis (1%), fertility preserved in a significant percentage of patients, filgrastim was incorporated after initial dose reduction or delay in 1991; a total of 84 patients (66%) received filgrastim^{ref1, ref2, ref3, ref4}
• STEAM (streptonigrin, thioguanine, cyclophosphamide, actinomycin-D, mitomycin C)
• SWOG CMFVP (cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone)
• T-2 protocol (dactinomycin, Adriamycin^©, vincristine, cyclophosphamide, radiotherapy)
• T-10 protocol (methotrexate, leucovorin / folinic acid calcium rescue, Adriamycin^©, cisplatin, bleomycin, cyclophosphamide, dactinomycin)
• T4N5 (T4 endolase V, liposome encapsulated)
• TAD (thioguanine, ara-C, daunomycin)
• TAD o TADex : dexamethasone 40 mg/day PO/IV days 1-4 + Adriamycin^© (doxorubicin) 50 mg/m²/day i.v. day 1 + thalidomide 100 mg/day p.o. days 1-28. Repeat cycle every 28 days for 4 cycles
• TC (thioguanine, cytarabine)
• T-CAP (Baker Antifol, cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• T-CAP III (triazinate, cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin)
• TD (thalidomide 200 mg/day PO daily, dexamethasone 40 mg/day days 1-4, 9-12, 17-20 for odd cycles and days 1-4 for even cycles. Repeat cycles every 28 days. Grade 3-4 thrombosis 12%, constipation (8%), rash (6%), dyspnea (4%), arrhythmia (2%), depression (2%), edema (2%), neuropathy (2%), sedation (2%), syncope (2%) => 3 treatment-related deaths on study. All 3 were within 1 month of starting therapy. Emetogenic potential level 1^ref)
• TEC (thiotepa, etoposide, carboplatin)
• TEMP (tamoxifen, etoposide, mitoxantrone, Platinol^© (cisplatin))
• tandem high-dose chemotherapy (THDC) with autologous stem cell transplantation. THDC consisted of melphalan (180 mg/m²) and escalating dose mitoxantrone (30-50 mg/m²) (MMt) for the first conditioning regimen, and thiotepa (500 mg/m²), carboplatin (800 mg/m²), and escalating dose etoposide phosphate (400-850 mg/m²), (ETCb) as the second regimen^ref
• T-MOP (thioguanine, methotrexate, Oncovin^© (vincristine), prednisone)
• TMC : thiotepa (750 mg/m²_BSA), mitoxantrone (40 mg/m²_BSA), and carboplatin (990 mg/m²_BSA)^ref
• TOAP (thioguanine, Oncovin^© (vincristine), cytosine arabinoside, prednisone)
• tositumomab + iodine I¹³¹-tositumomab: dosimetry day 0, g-camera scans 1 hours post-dosimetric dose and day 2, 3, or 4 and day 6 or 7. Therapy on a single day from day 8 to 14. See paper for specifics on dosimetry and treatment^ref
• TPCH (thioguanine, procarbazine, CCNU, hydroxyurea (HU))
• TPDCV (thioguanine, procarbazine, DBC, CCNU, vincristine)
• TRAP (thioguanine, rubidomycin, ara-C, prednisone)
• TVTG (topotecan 1 mg/m²/day as i.v. infusion on days 1–5, vinorelbine 20 mg/m² as i.v. push 0, 7, 14, 21 (only if the ANC > 500/ml), thiotepa 15 mg/m² i.v. over 4 h on day 2, gemcitabine 3600 mg/m2 per dose i.v. infusion over 6 h on day 7, dexamethasone 45 mg/m²/day p.o. t.i.d. on days 7–14, and G-CSF 300 mg s.c. or i.v. since day 7 and continue until ANC >500/ml))
• VA (vincristine, Adriamycin^©)
• VAAP (vincristine, L-asparaginase, Adriamycin^©, prednisone)
• VAB 1 (vinblastine, actinomycin-D, bleomycin)
• VAB 2 (vinblastine, actinomycin-D, bleomycin, cisplatin)
• VAB 3 (vinblastine, actinomycin-D, bleomycin, cisplatin, chlorambucil, cyclophosphamide)
• VAB 4 (vinblastine, actinomycin-Dbleomycin, cisplatin, cyclophosphamide)
• VAB 5 (vinblastine, actinomycin-D, bleomycin, cisplatin, cyclophosphamide)
• VAB 6 (cyclophosphamide, dactinomycin, vinblastine, bleomycin, cisplatin)
• VABCD (vinblastine, Adriamycin^©, bleomycin, CCNU, DTIC)
• VAB-V (vinblastine, actinomycin-D, bleomycin, cyclophosphamide, cisplatin)
• VABCD (vinblastine, Adriamycin^©, bleomycin, CCNU,DTIC)
• VAC (vincristine, actinomycin-D, cyclophosphamide or vincristine, Adriamycin^©, cyclophosphamide)
• VACA (vincristine, actinomycin-D, cyclophosphamide, Adriamycin^©)
• VACAD (vincristine, Adriamycin^©, cyclophosphamide, actinomycin-D, dacarbazine)
• VACOP-B : VePesid^© (etoposide) 50 mg/m²/day i.v. on day 1 of weeks 3, 7, 11 or 100 mg/m²/day p.o. on day 2+3 of weeks 3, 7, 11, Adriamycin^© (doxorubicin) 50 mg/m²/day i.v. day 1 of weeks 1, 3, 5,  7, 9, 11, cyclophosphamide 350 mg/m²/day i.v. on day 1 of weeks 1, 5, 9 , Oncovin^© (vincristine) 1, 2 mg/m²/day i.v. on day 1 of weeks 2, 4, 6,  8, 10, 12, prednisone 75 mg–100 mg abs. p.o. on days 1–7 of weeks  1–12, and bleomycin 10 mg/m²/day i.v. on day 1 of weeks 2, 4, 6,  8, 10, 12 (O’Reilly SE, Hoskins P, Klimo P. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 1 (Suppl): 17)
• BP-VACOP : bleomycin, Platinol^© (cisplatin), VePesid^© (etoposide), Adriamycin^© (doxorubicin), cyclophosphamide, Oncovin^© (vincristine), prednisone
• VACP (VePesid^© (etoposide), doxorubicin (Adriamycin^©), cyclophosphamide, Platinol^© (cisplatin))
• VAD (see also DAV) (vincristine 0.4 mg/day IV continuous infusion days 1-4, doxorubicin (Adriamycin^©) 9 mg/m²/day IV continuous infusion days 1-4, dexamethasone 40 mg PO days 1-4, 9-12, 17-20. Repeat cycle every 28-35 days. Neutropenia grade 3 (15%), sepsis (30%), thrombocytopenia grade >= 2 (11%), infectious mortality (2%), sepsis (30%), catheter thrombus/infection (14%), cushingoid features (26%), diabetes requiring insulin (11%). Emetogenic potential days 1-4 level 2^ref).
• liposomal doxorubicin (Adriamycin^©) 40 mg/m² IV day 1, vincristine 2 mg IV day 1, dexamethasone 40 mg/day PO/IV days 1-4. Repeat cycle every 28 days. Neutropenia grade 3 (21%) or 4 (9%), anemia grade 3 (12%) or 4 (9%), thrombocytopenia grade 3 (9%), grade 3 mucositis (12%), palmar-plantar erythrodysesthesia (21%), deep vein thrombosis (3%), dehydration (3%) => due to a high incidence of palmar-plantar erythrodysesthesia (PPE=, vitamin B6 200 mg PO daily was added to patients who developed PPE. 1 patient developed CHF. Emetogenic potential day 1 level 3^ref
• VAD-DCEP : vincristine 2 mg i.v. on day 1, doxorubicin (Adriamycin^©) 50 mg/m² on day 1, dexamethasone 40mg/die i.v. days 1-4, 14-17), followed by 2 courses of DCEP plus G-CSF. PBSC were collected after each cycle in order to obtain a sufficient number of CD34⁺ cells for 2 transplants. The DCEP schedule was as follows: dexamethasone 40 mg/die for 4 days, and a 4-day continuous infusion of cyclophosphamide 400 mg/m²/die, etoposide 40 mg/m²/die and cisplatin 10 mg/m²/die. G-CSF, at a dose of 5 mg/kg, was started 48 hours after the end of chemotherapy until PBSC leukaphereses were concluded^ref.
• VAD/V (vincristine, Adriamycin^©, dexamethasone, verapamil)
• VAFAC (vincristine, amethopterin, 5-FU, Adriamycin^©, cyclophosphamide)
• VAI (vincristine, actinomycin-D, ifosfamide)
• VAM (VP-26-213, Adriamycin^©, methotrexate)
• VAMP (vincristine, Adriamycin^©, methotrexate, prednisone or vincristine, amethopterin, 6-mercaptopurine, prednisone)
• VAP (vincristine, Adriamycin^©, procarbazine or vincristine, L-asparaginase, prednisone)
• VAP-II (vinblastine, actinomycin-D, Platinol^© (cisplatin))
• VAT (vinblastine, Adriamycin^©, thiotepa or vincristine, ara-A, thioguanine)
• VATD (vincristine, ara-C, thioguanine, daunorubicin)
• VATH (vinblastine, Adriamycin^©, thiotepa, Halotestin^©(fluoxymesterone))
• VAV (VP-26-213, Adriamycin^©, vincristine)
• VB (vinblastine, bleomycin)
• VBA (vincristine, BCNU, Adriamycin^©)
• VBAP (vincristine, BCNU, Adriamycin^©, prednisone)
• VBC (vinblastine, bleomycin, cisplatin or VePesid^© (etoposide), BCNU, cyclophosphamide)
• VBD (vinblastine, bleomycin, DDP)
• VBM (vincristine, bleomycin, DDP or vincristine, bleomycin, methotrexate)
• VBMCP (vincristine 1-2 mg/m² IV day 1, BCNU 20 mg/m² IV day 1, melphalan 8 mg/m² per ora days 1-4, cyclophosphamide 400 mg/m² IV day 1, and prednisone 40 mg/m² po days 1-7 in 5-week cycles)
• VBMF (vincristine, bleomycin, methotrexate, 5-FU)
• VBP (vinblastine, bleomycin, Platinol^© (cisplatin))
• VC (VP-16, carboplatin)
• VcAD : Velcade^© (bortezomib), Adriamycin^© and dexamethasone
• VCAP (vincristine, cyclophosphamide, Adriamycin^©, prednisone)
• VCAP-I (VP-16, cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• VCF (vincristine, cyclophosphamide, 5-FU)
• VCMP (vincristine, cyclophosphamide, melphalan, prednisone)
• VCP (vincristine, cyclophosphamide, prednisone)
• VCP-I (VP-16, cyclophosphamide, Platinol^©(cisplatin))
• VDC : vincristine, doxorubicin, and cyclophosphamide
• VDD : Velcade^© (bortezomib), Doxil^© (pegylated liposomal doxorubicin) and dexamethasone
• VDP (vincristine, daunorubicin, prednisone)
• VeIP (Velban^© (vinblastine), ifosfamide, Platinol^© (cisplatin)
• VelDexMyo : Velcade^© (bortezomib) 1.3 mg/m² on days 1, 4, 8, 11 + dexamethasone 40 mg/m² day i.v. or p.o. at days 1, 2, 4, 5, 8, 9, 11, 12 + liposomal doxorubicin (Myocet^©) 50 mg/m² IV on day 4. Repeat cycle every 21 days for 4 cycles
• VEMP (vincristine, Endoxan^© (cyclophosphamide), 6-mercaptopurine, prednisone)
• VIC (vinblastine, ifosfamide, CCNU or VP-16, ifosfamide, carboplatin)
• VIE (vincristine, ifosfamide, etoposide)
• ViGePP (gemcitabine, vinorelbine, procarbazine and prednisone) for patients with refractory aggressive NHL not suitable for high dose therapy (HDT) and autologous stem cell transplant (ASCT)^ref
• VIP : VePesid^© (etoposide), ifosfamide, and Platinol^© (cisplatin)
• VIP-B (VP-16, ifosfamide, Platinol^© (cisplatin), bleomycin)
• VIP-E : mobilization therapy consisting of VP-16 500 mg/m², ifosfamide 1500 mg/m², Platinol^© (cisplatin) 50 mg/m² and epirubicin 50 mg/m² followed by 5 µg/kg body weight rhG-CSF (Brugger W, Gramatzki M, Mertelsmann R et al. Early high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation (PBPC-T) in patients with high-risk aggressive non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1995; 14: 326a (Abstr))
• VLP (vincristine, L-asparaginase, prednisone)
• VM : Velcade^© (bortezomib), melphalan
• VM-26PP (VM-26 / teniposide, procarbazine, prednisone)
• VMAD (vincristine, methotrexate, Adriamycin^©, actinomycin-D)
• VMC (VP-16, methotrexate, citrovorum factor)
• VMCP (vincristine, melphalan, cyclophosphamide, prednisone)
• VMP :
• VePesid^© (etoposide), mitoxantrone, prednimustine
• Velcade^© (bortezomib) 1.3 mg/m² days 1, 4, 8, 11, 22, 25, 29, 32, melphalan 9 mg/m² days 1-4, prednisone 60 g/m² days 1-4 (4 6-week cycles), followed by Velcade^© (bortezomib) 1.3 mg/m² days 1, 8, 15, 22, melphalan 9 mg/m² days 1-4, prednisone 60 g/m² days 1-4 (5 5-week cycles)
• VMPT : Velcade^© (bortezomib) 1-1.6 mg/m², melphalan 6 mg/m², prednisone 60 mg/m², thalidomide 100 mg
• VNCOP-B : vincristine 2 mg iv week 2, 4, 6, 8, (Novantrone^©) mitoxantrone 10 mg/m² iv week 1, 3, 5, 7, cyclophosphamide 300 mg/m² iv week 1, 3, 5, 7, etoposide 150 mg/m² iv week 2, 6, prednisone 40 mg PO for 6 weeks then escalate in the last 2, and bleomycin 10 U/m² iv week 4, 8); G-CSF 5 mg/kg alternibus diebus subcutaneously since day 3 to day 7 of each interval. Neutropenia grade 4 (29%), grade 3 infections (11%), grade 1/2 anemia (< 10%), grade 1/2 thrombocytopenia (< 10%)^{ref1, ref2, ref3}
• VOCA (VP-16, Oncovin^© (vincristine), cyclophosphamide, Adriamycin^©)
• VOCAP (VP-16, Oncovin^© (vincristine), cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• VP (vincristine, prednisone)
• VP-16 + DDP (etoposide, cisplatin)
• VP-16-P (VP-16, Platinol^© (cisplatin))
• VP + A (vincristine, prednisone, L-asparaginase)
• VPB (vinblastine, Platinol^© (cisplatin), bleomycin)
• VPBCPr (vincristine, prednisone, vinblastine, chlorambucil, procarbazine)
• VPCA (vincristine, prednisone, cyclophosphamide, ara-C)
• VPCMF (vincristine, prednisone, cyclophosphamide, methotrexate, 5-FU)
• VP + L-asparaginase (vincristine, prednisone, L-asparaginase)
• VPP (VePesid^© (etoposide), Platinol^© (cisplatin))
• VPVCP (vincristine, prednisone, vinblastine, chlorambucil, procarbazine)
• VRD : Velcade^© (bortezomib), Revlimid^© lenalidomide and dexamethasone
• VTD : Velcade^© (bortezomib) 1.6 mg/m², thalidomide 100 mg, dexamethasone 20 mg
• ZeBEAM : Zevalin (ibritumomab tiuxetan) + BEAM^{ref1, ref2}